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Summary 
 
Sleeping sickness or Human African trypanosomosis (HAT) is a protozoal disease that is 
transmitted by tsetse fly vectors in Africa. Sleeping sickness due to T. b. gambiense is a major 
public health problem in countries in central and western Africa including Angola, Uganda, 
Democratic Republic of Congo (DRC) and Sudan. High rates of relapses (>20%) following 
melarsoprol treatment have been reported in many treatment centres including the MSF-F 
treatment centre at Ibba in south Sudan. The treatment failures could be due to individual 
(patients) variation in the drug pharmacokinetics, the patient’s immune responses, or drug 
resistant parasites.  
 
There is a growing interest in the elucidation of the reason(s) for relapses after melarsoprol 
treatment. Since the drug levels in blood or CSF do not differ between relapse and 
successfully treated patients, drug resistance has been suggested as a likely cause for 
melarsoprol treatment failures. There are no recently isolated parasites from high-relapse 
areas and hence detailed studies have been hindered. The objective of this PhD study was to 
isolate and characterize (phenotypically and genotypically) T. b. gambiense from HAT 
patients in the MSF-F treatment centre at Ibba. 
 
In a first step, the protocols for the isolation of bloodstream forms of the parasite needed to be 
improved. As such, the suitability of the commercial cryomedium Triladyl developed for 
bull semen was evaluated. We found that, the cryopreservation of T. b. gambiense in this 
medium led to a better survival of the trypanosomes than in the standard 10% glycerol. The 
samples (blood (50) and CSF (2)) from HAT patients were therefore cryopreserved using 
Triladyl® and stored at -150oC in nitrogen vapour in a dry shipper. In the laboratory, attempts 
to propagate the isolated parasites in rodents were carried out. Of the 42 parasite positive 
isolates, 18 (43%) could be propagated in laboratory rodents (immunosuppressed Mastomys 
natalensis and SCID mice). Stabilates of these T. b. gambiense isolates are stored in two 
cryobanks at the Trypanosomiasis Research Centre (TRC) of the Kenya Agricultural Research 
Institute (KARI), Nairobi and the Swiss Tropical Institute (STI), Basel. 
 
After the initial isolation of these T. b. gambiense isolates in immunosuppressed M. natalensis 
or SCID mice, further in vivo propagation could be done in various immunosuppressed rodent 
species (Swiss White mice, M. natalensis, C57/bl, C3H, and BALB/C). The highest 
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parasitaemia were achieved in C57/bl and BALB/C mice. The rodents however had to be 
immunosuppressed with cyclophosphamide at 300mg/kg prior to infection and repeated once 
a week at 200mg/kg. This scheme (cryopreservation and subsequent propagation) allows the 
isolation of T. b. gambiense from various endemic areas and therefore enhances monitoring of 
drug resistant trypanosomes.  
 
The eighteen T. b. gambiense isolates were found to be sensitive to melarsoprol, melarsen 
oxide, and diminazene. The gene that codes for the P2 transporter, TbATI, was amplified by 
PCR and sequenced. The sequences were almost identical to the TbAT1sensitive reference, 
except for one point mutation, C1384T resulting in the amino acid change proline-462 to 
serine. None of the described TbAT1resistant-type mutations were detected. In summary we 
found, in a sleeping sickness focus where melarsoprol had to be abandoned due to the high 
incidence of treatment failures, no evidence for drug resistant trypanosomes or for 
TbAT1resistant-type alleles of the P2 transporter.  
 
In conclusion, our findings cast doubts on the current suggestion that melarsoprol resistant 
parasites are the cause of the high rate of treatment failures reported. However, it is important 
to note that the number of isolates tested was still small and it is vital that more isolates, 
especially from relapse patients be tested 
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Zusammenfassung 
 
Schlafkrankheit, auch humane afrikanische Trypanosomosis (HAT) genannt, ist eine 
Protozoenkrankheit, die in Afrika übertragen wird. Schlafkrankheit vom Typ T.b. gambiense ist 
ein grosses Problem im öffentlichen Gesundheitswesen von Ländern Zentral- und Westafrikas wie 
Angola, Uganda, Demokratische Republik Kongo (DRC) und Sudan. Hohe Rückfallraten (>20%) 
nach Melarsoprol Behandlung wurden in vielen Zentren beobachtet, darunter auch im MSF-F 
Zentrum in Ibba im Süden Sudans. Diese Rückfälle könnten auf Unterschiede in der  
Pharmakokinetik des Medikamentes in Patienten, auf die Immunantwort des jeweiligen Patienten 
oder auf resistente Parasiten zurückzuführen sein. 
 
Es besteht ein grosses Interesse herauszufinden, was die Gründe für die hohe Rückfallrate 
nach Melarsoprol Behandlung sind. Da die Medikamentenspiegel im Blut oder CSF von 
Patienten, die geheilt wurden oder einen Rückfall erlitten, sich nicht als unterschiedlich 
herausstellten, wird Medikamentenresistenz mit grosser Wahrscheinlichkeit als der Grund für 
fehlgeschlagene Behandlungen betrachtet. Da es aber keine kürzlich isolierten 
Parasitenisolate aus dieser Gegend gibt, konnten bis anhin keine detailierten Studien 
durchgeführt werden. Das Ziel dieser PhD Arbeit war es, T. b. gambiense Isolate von HAT 
Patienten im MSF-F Behandlungszentrum in Ibba zu isolieren und zu charakterisieren 
(phänotypisch und genotypisch). 
 
In einem ersten Schritt wurden die Protokolle zur Isolierung von Blutformen des Parasiten 
verbessert. Hierzu wurde untersucht, wie geeignet das für Stiersamen entwickelte, 
kommerziell erhältliche Kryomedium Triadyl wirklich ist. Wir haben dabei festegestellt, 
dass die Kryopräservierung von T. b. gambiense in diesem Medium, verglichen mit dem 
standardisierten 10% Glycerin-Protokoll, zu einem besseren Überleben der Trypanosomen 
geführt hat. Die Proben (Blut (50) und CSF (2)) von HAT Patienten wurden darum in 
Triladyl kryopräserviert und bei -150°C in flüssigem Stickstoff in einem „dry shipper“ 
gelagert. Im Labor wurden Propagationsversuche mit den isolierten Parasiten in Nagern 
durchgeführt. Von den 42 parasitierten Isolaten konnten 18 (43%) in Labornagern 
(immunosuprimierte Mastomys natalensis und SCID Mäuse) propagiert werden. Stabilate von 
diesen T. b. gambiense Isolaten werden in zwei Kryobanken am „Trypanosomiasis Research 
Centre (TRC) of KARI, Nairobi“ und dem „Swiss Tropical Institute“ (STI) gelagert. 
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Nach der Gewinnung von diesen T. b. gambiense Isolaten aus immunosupprimierten M. 
natalensis oder SCID Mäusen, konnten die Parasiten in verschiedenen immunosupprimierten 
Nagerspezies (Swiss White Mäusen, M. natalensis, C57/bl, C3H, und BALB/C) 
weiterpropagiert werden. Die höchsten Parasitämien wurden in C57/bl und BALB/C Mäusen 
erreicht. Die Nager mussten allerdings mit Cyclophosphamid immunosupprimiert werden 
(vor der Infektion mit 300mg/kg Cyclophosphamid, anschliessend einmal wöchentlich mit 
200mg/kg). Dieses Schema (Kryopraeservation und anschliessende Propagation) wird die 
Isolation von T. b. gambiense aus verschiedenen endemischen Gebieten ermöglichen und 
darum das „monitoring“ von resistenten Trypanosomen vereinfachen. 
 
Die 18 propagierten T. b. gambiense Isolate wurden als sensitiv gegenüber Melarsoprol, 
Melarsenoxid, und Diminazene identifiziert. Das Gen kodierend füer den P2 Transporter, 
TbATI, wurde mittels PCR amplifiziert und sequenziert. Die Sequenzen waren fast gpeich wie 
die TbAT1sensitive Referenz, mit Ausnahme einer Punktmutation, C1384T, die in einer 
Aminosäureänderung von Prolin-462 zu Serin resultierte. Keine der beschriebenen 
TbAT1resistant-Typ Mutationen konnten beobachtet werden. Zusammenfassend haben wir in 
einem Schlafkrankheits-Fokus, wo Melarsoprol Behandlungen aufgrund von hohem Auftreten 
von Behandlungsmisserfolgen aufgegeben werden mussten, keine Hinweise auf resistente 
Trypanosomen oder TbAT1resistant-Typ Allele vom P2 Transporter gefunden. 
 
Unsere Ergebnisse zweifeln darum die momentan vorherrschende Meinung, dass melarsoprol-
resistente Parasiten der Grund für die hohe Rate an Behandlungsmisserfolgen sind, an. Es 
muss allerdings hevorgehoben werden, dass die Anzahl der von uns getesteten Isolate klein 
war und es wichtig wäre mehr Isolate, und vor allem Isolate von „relapse“ Patienten, zu 
testen.
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CHAPTER 1: Introduction 
Prevalence of Human African Trypanosomosis  
 
Sleeping sickness or Human African Trypanosomosis (HAT) is a protozoan disease that is 
transmitted only in Africa. It is an ancient disease with the first records dating to the 14th 
century. It is the third most important vector borne parasitic disease (Molyneux 1996). 
Although the figures for HAT are relatively small compared to other diseases, HAT is fatal if 
untreated and has the propensity to develop into epidemics making it a major public health 
problem.  
 
The disease is only endemic in areas where tsetse flies of the genus Glossina (the only vector) 
are found. As such its occurrence is rather focal with ecological limits of tsetse fly distribution 
from approximately 14oN (West Senegal) and 10oN (East, Somali) to 20oS at the northern 
fringes of the Kalahari and Namibian desert, depending on climate and vegetation (Molyneux 
1996). The prevalence and distribution of the disease is as shown in Figure 1.  
 
 
 
Figure 1: Distributions of sleeping sickness or Human African Trypanosomosis (Kuzoe 
1993;WHO 1998a)  
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By the late 1950s, the incidence of sleeping sickness had been greatly reduced by mass 
campaigns including active case detection, treatment, chemoprophylaxis and vector control. 
However, sleeping sickness has reemerged as a major threat to health, with waves of new 
outbreaks and epidemics. Resurgence of the disease has been noted from large portions of 
Africa, with epidemic levels being reported in Democratic Republic of Congo (DRC), 
Angola, Sudan and Uganda (WHO 1998b). It is estimated that HAT threatens about 60 
million people in 36 countries in sub-Saharan Africa. The prevalence of the disease is 
estimated at 300,000 to 500,000 with an annual mortality of approximately 50,000 (WH0 
2004).  
 
There are many causes of this resurgence but in particular, the spread of warfare in many 
endemic countries led to a breakdown of control programs. Other factors leading to new 
outbreaks are the emergence of more virulent parasite strains, changes in climate and 
vegetation, and movement of animals that are reservoirs of the disease.  
 
Situation of HAT in Sudan  
 
Sudan is a vast country (2.5 million km2) with considerable variation in climate. Epidemics of 
sleeping sickness have been occurring in the South Sudan since the early 20th century. The 
epidemics have mainly been reported in the southern and south western parts of the country 
bordering Uganda, DRC and Central African Republic (CAR). The foci include Raga, Yei, 
Kajokeji, Nimule, Tambura, and Yambio (Duku 1981). 
 
In these foci, control has largely depended on international organizations and non 
governmental organizations (NGO), but the civil strife in particular (since 1959) disrupted the 
control programs. For instance, in the 1980s the Belgian-Sudanese control programme limited 
the incidence of HAT in the Sudan province of western Equatoria. When the fightings 
intensified in the 1990 this control programme collapsed. This resulted in absence of HAT 
control for more than a decade and led to resurgence of the disease with several foci reporting 
a prevalence exceeding 5%. Accurate data on the extent of the disease are limited. It is 
estimated that 10 million people are at risk of infection and thousands of persons are infected 
annually (Moore & Richer 2001).  
 
Introduction 
__________________________________________________________________________ 
 9 
As indicated earlier there are many active foci of HAT in south Sudan and control programs 
are mainly run by various NGOs: Malteser Germany in Yei county (ISCTRC 2005); 
International Medical Corps (IMC) in Tambura county, Médecins Sans Frontières (MSF) in 
Maridi, Mundri and Kajokeji Counties. There are only a few reports, restricted to a few of 
these foci and thus the actual situation of HAT in south Sudan is therefore not very clear.  
 
In Tambura County a survey carried out between 1996 and 1997 indicated that the prevalence 
had doubled and the villages affected had increased from 54% to 100% since 1988. Another 
survey in 1997 estimated 5,000 HAT cases and a prevalence of 23%. High prevalence foci 
included Ezo (37%) in the southern part of Tambura county and Source Yubu (21.5%) 
(Moore et al. 1999). A recent study has shown that Maridi county has the highest prevalence 
(29%) in western Equatorial (Moore & Richer 2001). The prevalence of HAT is as shown in  
Figure 2. 
 
 
 
Figure 2: Prevalence of sleeping sickness in Southern Sudan, 1998 (Adapted from 
Moore & Richer (2001)). 
The parasite 
Taxonomy  
 
Sleeping sickness was recognized in Africa for centuries but its cause was not discovered 
until about 1900. Sir Bruce identified the causative agent as a protozoan trypanosome that 
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was transmitted by the tsetse fly (Soltys ( 1953). The trypanosome causes disease in both man 
and his domestic animals. 
 
Trypanosomes are classified under the sub-kingdom of protozoa, phylum Sarcomastigophora, 
order Kinetoplastida, family Trypanosomatidae and genus Trypanosoma. This genus has two 
groups, Stercoraria and Salivaria (Hoare 1970). Stercoraria contain genera in which the 
trypanosome completes its development in the hindgut and transmission is by fecal 
contamination. The species in Stercoraria include T. cruzi that causes Chagas disease in South 
America.  
 
The salivarian group completes development in the salivary glands, and transmission is by 
inoculation of metacyclics with the saliva. The main genera in this group are: Duttonella 
(species: Trypanosoma vivax, and T. uniforme; Nannomonas (species: T. congolense and T. 
simiae); Pycnomonas (species: T. suis) and Trypanozoon (species: T. brucei brucei, T. b. 
rhodesiense, T. b. gambiense, T. evansi and T. equiperdum) (Hoare 1970). Duttonella, 
Nannomonas, Pycnomonas and some species in Trypanozoon (T. brucei brucei, T. evansi and 
T. equiperdum) cause disease in animals.  
 
The disease in man is caused by T. b. rhodesiense and T. b. gambiense. Trypanosomes that 
cause disease in animals are not infective to humans due to their sensitivity to human serum 
that hinders their survival in man. However, in individuals lacking the lytic factor, 
trypanosome infection is possible. Indeed a case of human trypanosomosis caused by T. 
evansi has recently been reported in India (Joshi et al. 2005).  
 
Distribution of T. b. gambiense and T. b. rhodesiense 
 
Trypanosoma b. rhodesiense is restricted to East Africa while T. b. gambiense is found in 
central and West Africa. The boundary between the distributions of the two parasites follows 
the Great Rift Valley. The separation is thought to have resulted from evolution of hominids 
(Welburn et al. 2001). Uganda is the only country where both diseases exist and recent 
reports indicate that there could be an overlap between T. b. gambiense and T. b. rhodesiense 
(Enyaru et al. 1999).  
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The two parasites are morphologically indistinguishable. Currently there are two tests based 
on molecular markers that distinguish T. b. rhodesiense from T. b. gambiense: The Serum 
Resistant Associated gene (SRA) is only found in T. b. rhodesiense and absent in T. b. 
gambiense (DeGreef et al. 1989); whereas T. b. gambiense specific glycoprotein gene 
(TgsGP), is present in T. b. gambiense but absent in T. b. rhodesiense (Berberof et al. 2001). 
In the event of suspected overlap, these test(s) can be used to distinguish the infecting 
parasite. 
 
The trypanosome life cycle  
 
Tsetse flies are the only vector of Trypanosoma brucei. There are about 20 species of tsetse 
flies but only a few transmit the disease. The flies have an average life span of between one to 
six months and live in warm, shady and humid areas. The parasites are ingested from an 
infected mammalian host by the blood-sucking insect vector. Once infected, the tsetse flies 
remain infective for life and a small number of infected tsetse flies can maintain endemic 
transmission cycles at relatively high levels.  
 
During feeding, the tsetse fly takes up trypanosomes from the host. In the ectoperitrophic 
space between midgut epithelium and the peritrophic membrane, the stumpy trypomastigotes 
transform to procyclics. After rapid proliferation (10-12 days) the procyclics move to the 
proventriculus and subsequently migrate as epimastigotes via the hypopharynx to the salivary 
glands. The attached epimastigotes further differentiate and emerge as mammal-infective 
metacyclic trypanosomes after 13-15 days. The developmental life cycle is shown in Figure 3. 
 
The infected fly will infect a mammalian host during feeding. Briefly, the biting tsetse fly 
deposits metacylic trypanosomes in the dermal tissues of the host. The metacylics rapidly 
transform into long slender bloodstream forms (BSF), which then multiply by binary fission 
and subsequently invade the lymphatic, blood system and later also the central nervous 
system. Besides these long slender forms, morphologically different, non-proliferating stumpy 
forms are observed at peak and declining parasitaemia in the blood of the host. It is these 
stumpy forms that are able to continue the life-cycle in the insect vector. 
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Figure 3: Trypanosoma brucei schematic representation of developmental cycle in a 
mammal and in the tsetse fly vector (Vickerman 1985) 
 
 
Only a small proportion of tsetse flies which have taken up trypanosomes develop a mature 
infection and this takes about 3-4 weeks. It has been found that only teneral flies can develop 
a mature infection. The reasons are not very clear but the current suggestions is that the lack 
of lectin and poorly developed peritrophic membrane make the teneral flies susceptible to 
trypanosome infection (Lehane & Msangi 1991). 
 
Introduction 
__________________________________________________________________________ 
 13 
 
The disease 
 
A few days after a tsetse bite, a painless nodular skin lesion (chancre) develops and lasts for 
about two weeks. At this initial stage, a satellite lymphadenopathy and fever with generalized 
malaise may be the only signs noted. As the trypanosomes invade the lymph, blood, bone 
marrow and tissue fluids, the patient experiences transient local oedema, sensational 
hyperaesthesia (Kerandels sign), intermittent fever accompanied by headaches, pains in the 
joints, splenomegaly and lymphadenopathy (Apted 1970). The disease progresses to the 
meningo-encephalitic stage (second stage), during which the parasites invade the 
cerebrospinal fluid (CSF) and brain tissues. This progressively leads to a variety of clinical 
manifestations, including headache, irritability, tremors, ataxia, convulsions, personality 
changes, daytime somnolence, pronounced wasting and coma (Dumas & Boa 1988).  
 
Both infections by T. b. rhodesiense and T. b. gambiense follow this sequence of infection 
stages, but with marked differences in rate of progression. Generally T. b. rhodesiense is 
regarded as an acute infection, with progression to 2nd.stage occurring in a matter of weeks. It 
leads to death (>80%) within six months of the onset of illness (Odiit et al. 1997). However, 
T. b. gambiense generally causes a chronic disease in which progression to 2nd.stage may take 
several months or longer, and the 2nd stage may take several years (Barrett et al. 2003). 
Nevertheless there are reports of wide variation in disease severity in patients (Sternberg 
2004). Generally, however, the Rhodesian disease is viewed as a compressed form because 
most symptoms as well as the neuropathological changes are the same in both forms 
(Kristensson et al. 2002)  
 
The disease caused by T. b. gambiense is more widespread than T. b. rhodesiense (95% verses 
5%). In addition, the HAT resurgences recently reported are mainly due to T. b. gambiense. 
Sleeping sickness due to T. b. gambiense is a major public health problem in DRC, Angola, 
Uganda and south Sudan (WHO 1998b).  
Diagnosis of Gambian sleeping sickness 
 
Humans constitute the epidemiologically important reservoir of T. b. gambiense and the 
cornerstone of control is dependent on case detection through population screening, followed 
by treatment of those diagnosed positive. 
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Many tests have been developed for diagnosis of HAT, including: latex agglutation test 
(Buscher et al. 1999); ELISA tests (Buscher et al. 1999;Nantulya 1988;Nantulya et al. 1992); 
immune trypanolysis test (Van Miervenne et al., 1995); polymerase chain reactions 
(Kanmogne et al. 1996;Kyambadde et al. 2000;Penchenier et al. 2000). Nevertheless, some of 
these tests are not in use, either because the test is still under evaluation or requires 
specialized facilities that are unavailable in laboratories in endemic countries. In the endemic 
countries, primary diagnosis is done serologically by use of the card agglutination test for 
trypanosomosis (CATT) (Magnus et al. 1978), and confirmation done by parasitological test. 
This is then followed by determination of the stage of disease. 
 
Serological and parasitological diagnosis 
 
A field CATT kit is available and the test is rapid and easy to perform, allowing screening of 
several hundred people in a day. This test has high sensitivity (Moore & Richer 2001) but 
false negatives have been reported in north western Uganda (Moore & Richer 2001) and in 
southern Sudan (MSF 2001). The test was developed from LiTat 1.3 antigen (Magnus et al. 
1978) and false negatives may indicate the presence of another variant of trypanosomes in this 
region. Nevertheless, CATT reduces the workload of further tests to be done and considerably 
increases the detection rate. Patients that are CATT-positive undergo further parasitological 
test: microscopic examination of both the venous blood (using the haematocrit method (Woo 
1970) and lymph node aspirate.  
Stage determination 
 
The stage of the disease is determined in accordance with the recommendations by WHO. 
Cerebrospinal fluid (CSF) is collected through a lumbar puncture and examined for the 
presence of trypanosomes, the number of white cells, and total protein concentration. If at 
least one of these parameters is abnormal the patient is considered to be at the 2nd stage 
disease. Detection of trypanosomes in CSF allows immediate classification of a patient in 
2nd.stage disease. In non-specialized laboratories trypanosomes are generally detected by 
direct examination of CSF, but sensitivity for detection can be increased by centrifugation of 
the CSF sample (Cattand et al. 1988;Woo 1970) 
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The CSF white cell count (WCC) is the most widely used parameter for stage determination. 
Patients with less than 5 cells/µl are classified as 1st.stage while those with more than 5 
cells/µl are classified as 2nd stage (WHO 1998). Although this criterion of staging is still 
common in most hospitals, studies (Doua et al. 1996;Miezan et al. 1994) have shown that the 
5 cells criterion is insensitive and a number of patients in 1st.stage of the disease will still be 
having up to 20 cells/µl in the CSF. Various methods for quantifying protein in the CSF are 
available including precipitation and colorimetric methods. The cut-offs are dependent on the 
particular test method. 
 
However, diagnosis of HAT by these methods does not always give the true status of the 
infection and there is a continuous search for alternative diagnostic procedures. Ideally, the 
tests should be cheap, less invasive and easy to perform under field conditions. 
 
Chemotherapy of Gambian sleeping sickness 
 
Control of T. b. gambiense depends mainly on chemotherapy. Treatment of diagnosed 
patients relies on a small number of drugs: pentamidine (pentamidine isethionate BP, 
Pentacarinat, Aventis, France), melarsoprol (Mel B, Arsobal, Aventis, France), eflornithine 
(Ornidyl, Aventis, France) and nifurtimox (Lampit, Bayer, Germany). The choice of drug for 
treatment further depends on the stage of the disease of the patient. 
Pentamidine  
 
The treatment of first stage T. b. gambiense disease relies mainly on pentamidine, a diamidine 
that was introduced in 1941. It is not clearly understood how pentamidine affects the 
parasites. Some of its effects include inhibition of trypanosomal S-adenosyl-L-methionine 
decarboxylase leading to reduced polyamine synthesis, competition with polyamines for 
binding to nucleic acids, particularly kinetoplast DNA (Berger et al. 1993;Williamson et al. 
1975).  
 
The recommended dosage is 4 mg/kg bwt administered daily for seven days by deep 
intramuscular injection. The side effects of pentamidine are considered minor and include; 
sterile abscesses or necroses at the injection site, nausea, vomiting, hypotension, 
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hypoglycemia, a feeling of faintness and tachycardia (Pepin & Milord 1994). The cure rate 
ranges from 93 to 98% and has not changed significantly over decades. 
 
Suramin 
Suramin was introduced in 1922. It is a sulphonated naphtylamine that is negatively charged 
at physiological pH. Suramin binds to plasma proteins and the plasma-protein-bound complex 
is taken up by trypanosomes by pinocytosis. It inhibits many dehydrogenases and kinases 
(Hawking 1978), thymidine kinase (Chello & Jaffe 1972) and dehydrofolate reductase (Jaffe 
et al. 1972). Suramin also inhibits the glycolytic enzymes (Willson et al. 1993), but only 
indirectly because the phospholipids bilayer prevents its uptake into the glycosome. Suramin 
is effective in the treatment against 1st stage infections of T. b. gambiense and T. b. 
rhodesiense but it is exclusively used in the Rhodesian disease. Usually, 5 injections of 
2mg/kg are administered at intervals of 5-7 days. Cure rates of 100% have been reported 
(Apted 1980) but  treatment failures have also been recorded (Wellde et al. 1989b).  
 
Side effects, such as fever, photophobia, vomiting, flatulence, constipation and hyperaethesia 
have been observed.  In rare cases fatal side effects including kidney damage and changes in 
blood picture may occur. Lethal idiosyncratic reactions (anaphylactic shock) have also been 
reported, especially when there is concomitant onchocerciasis (Van Nieuwenhove 2000).  
 
At the first stage of the disease, treatment is cheaper and leads to minor adverse effects. Most 
patients are, however, presented for treatment when the CNS is already involved. At the 
second stage of the disease, the drugs used are melarsoprol, eflornithine or nifurtimox.  
Eflornithine  
 
Eflornithine was initially developed for cancer chemotherapy and in 1990, intravenous 
eflornithine was approved for treatment of the meningoencephalic stage of sleeping sickness. 
It is a selective irreversible inhibitor of ornithine decarboxylase, blocking polyamine 
biosynthesis. Polyamines are essential for growth and multiplication of the trypanosomes. As 
such eflornithine is cytostatic rather than cytotoxic and a competent immune system is 
essential for parasite clearance (Bacchi et al. 1980).  
 
The current recommended dosage is 100 mg/kg body weight given intravenously every 6 
hours for 14 days. The frequent side-effects observed are leucopenia, anaemia and diarrhoea 
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(Pepin & Milord 1994). In addition, abdominal pain, vomiting, dizziness, convulsions and 
thrombocytopenia are reported.  
The major drawback of the intravenous eflornithine is related to its high cost of treatment and 
the inconveniences of administration, especially in understaffed rural hospitals of the disease-
endemic countries. As such the current challenges are to evaluate the oral administration of 
DFMO (Na-Bangchang et al. 2004). 
 
Nifurtimox 
 
Nifurtimox was introduced in the 1960's for treatment of South American trypanosomosis 
(Chagas disease). The mode of action is not completely elucidated. It is suggested that free 
radicals and further superoxide and hydrogen peroxide are formed by cyclical reduction and 
oxidation of the nitro group of nifurtimox. Those free radicals bind to cellular components 
such as DNA, membrane lipids and proteins causing death of the parasite.  
 
Nifurtimox is not registered for HAT but is used on compassionate basis. The treatment 
regimens used are very variable but the most widely used schedule is 15 mg/kg body 
weight/day in three oral doses for two weeks in adults and 20 mg/kg body weight/day in 
children. Nifurtimox has shown promise in the treatment of 2nd.stage of T. b. gambiense 
infections in refractory patients alone and in combination with melarsoprol or eflornithine 
(Pepin et al. 1992b). 
 
Common side effects of nifurtimox are anorexia, jaundice, nausea, vomiting, rash and fever. 
In addition, several cases of a reversible cerebellar syndrome incuding seizures, coma, and 
confusion were observed (Pepin et al. 1992b) 
 
Melarsoprol 
 
Melarsoprol is the first-line drug for treatment of second stage disease (Van Nieuwenhove 
2000). It is a combination of the trivalent organic arsenical melarsen oxide (Mel OX) with the 
heavy metal chelator BAL (British Anti-Lewisite, dimercaprol). Melarsoprol’s metabolite- 
Mel OX is the active drug (Keiser et al. 2000). Mel OX inhibits the polyamine synthetic 
pathway in the trypanosome and its primary target is trypanothione (Fairlamb et al. 
1989;Keiser et al. 2000). Trypanothione is the major thiol-containing molecule in 
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trypanosomes and is essential for maintaining an intracellular reduced environment by 
detoxifying oxygen radicals. As such, the binding of Mel OX to trypanothione leads to 
oxidative stress in the trypanosomes. 
 
The World Health Organisation (WHO) recommends four different schedules to be used, 
depending on the parasite and region (WHO, 1986). Further, differences in duration and mode 
of therapy have been observed depending on the country, local habits and the hospital 
involved. An alternative schedule was first proposed in 1995 (Burri et al. 1995) and was 
recommended in 2003 by the International Scientific Council of Trypanosomiasis Research 
and Control (ISCTRC) as the schedule of choice in T. b. gambiense endemic countries. In this 
schedule the patient receives 2.2 mg/kg bwt for ten consecutive days, intravenously (Burri et 
al. 2000;Schmid et al. 2004;Schmid et al. 2005). A shorter course of treatment is an important 
advancement since it is less burdensome for the patient, families, and health workers and is 
more cost-effective.  
 
The most common adverse effects of melarsoprol treatment are fever, diarrhoea, pain in chest, 
necrosis at the site of injection due to leakage during administration. The worst is severe post-
treatment reactive encephalopathy (PTRE) in about 5-10% with a fatal outcome of 1-5% of 
treated patients (Pepin & Milord 1994). Corticoids, in dosage of 1 mg/kg per day, have been 
used for prevention of fatal complications during treatment with melarsoprol on the 
assumption that the myocarditis and encephalopathy of sleeping sickness are largely of 
immunopathological origin. However, conclusive evidence of their value has not been 
demonstrated. In view of the high costs and doubtful evidence, routine use is not 
recommended 
 
Melarsoprol treatment failures 
 
Treatment with melarsoprol results in a normal failure rate of 3 - 9% attributed to patient-
related factors (concomitant infections, nutritional status, etc). In the recent years higher 
treatment failure rates (> 20%) have been reported in the endemic areas of T. b. gambiense 
including, Uganda (Legros et al. 1999), Mbanza Kongo in northern Angola (Ruppol et al., 
1977) and southern Sudan (Legros et al. 1999;Moore & Richer 2001;Nieuwenhove et al. 
1985). As a result of these high treatment failure rates, many SS treatment centers have 
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shifted from using melarsoprol to eflornithine as the first line treatment. The causes of these 
treatment failures are not yet clear. 
 
Treatment failures may be due to various factors including; the patient’s immune responses, 
individual (patients) variation in drug pharmacokinetics, or melarsoprol resistance in the 
infecting parasites. 
 
Patient’s immune status 
 
Some of the drugs require a competent immune system in order to be fully effective. Diseases 
or conditions that lead to immunosuppression such as human immunodifiency virus (HIV) 
could therefore lead to low treatment success. Indeed, Milord et al. (1992) found that HAT 
patients co-infected with HIV responded less to eflornithine treatment than seronegative ones. 
The role of HIV in melarsoprol treatment failures is not established. Earlier studies have 
shown that HIV has no impact on epidemiology of HAT (Louis et al. 1991;Meda et al. 
1997;Pepin et al. 1992a) because HIV was then relatively low in rural areas where HAT is 
endemic. Today, the situation has changed and the prevalence of HIV is high in rural areas 
and its role needs to be re-assessed. Other concomitant infections that cause 
immunosuppression such as malaria might also affect the prognosis of the disease. There are 
reports of co-infections of sleeping sickness and malaria (Schmid et al. 2004;Wellde et al. 
1989c;Wellde et al. 1989a;Schmid et al. 2004) and sleeping sickness and Loasis (Enyaru 
2002). 
 
 Pharmacokinetics of melarsoprol  
 
Melarsoprol was introduced for the treatment of HAT before its pharmacokinetic profile was 
fully understood. It is only recently that its pharmacokinetics was established. Melarsoprol 
has an average half-life of 42 hours and average total clearance of 1 ml/min kg (Burri et al., 
2001). Its concentration varies with time and from patient to patient. Immediately after 
treatment, the mean plasma levels are approximately 6 µg/ml (Burri & Keiser 2001) but drop 
rapidly to 1.3 µg/ml 24 hours later. However 120 hours later the levels drop even further to 
220 ng/ml (Burri et al. 1993). The concentrations in the CSF are much lower, a maximum of 
260 ng/ml, dropping to 64 ng/ml 24 hours after the last injection. In some patients the levels 
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were undetectable. The variation of the concentration with time in the CSF has not been done 
but it is postulated that the general trend would be a decrease with time.  
 
To eliminate all trypanosomes, melarsoprol must be available in sufficient concentration in all 
body fluids and tissues. The sensitivities of trypanosome isolates also vary and sensitive 
strains appear to have the minimum inhibitory concentration (MIC) of around 1-30 ng/ml. 
Concentration of melarsoprol in the CSF is much lower (only 1-2%) than in plasma and CSF 
concentration is therefore critical in parasite clearance. Indeed it is believed that relapses 
result from parasites surviving in the CNS. As stated earlier the concentration of melarsoprol 
varies between patients. However, there was no difference in the concentrations in the CSF 
between relapse patients and cured patients (Brun et al. 2001;Burri & Keiser 2001). This may 
indicate that high treatment failure rate reported might not be due to low levels of melarsoprol 
in the CSF of relapse patients.  
 
A lot of emphasis has been put on concentrations of melarsoprol in body fluids and rather less 
attention has been paid to its concentration in the tissues. Unfortunately, deep tissues are less 
accessible to the drugs and thus parasites localized here would be exposed to low 
concentrations. Indeed, T. b. gambiense is tissue-invasive and therefore has high affinity for 
deep tissue. This means that even a sensitive trypanosome isolate localized in the deep tissues 
may not be cleared. Very few studies have addressed this possibility and therefore there is 
need for more investigation. 
 
Drug resistance in trypanosome populations 
 
Melarsoprol is lipophilic and can diffuse across the trypanosome plasma membrane. In 
plasma however, melarsoprol is rapidly cleared (96% within 1 hour and 100% in 24 hours) to 
form active metabolites, including melarsen oxide. Melarsen oxide (Mel OX), a metabolite of 
melarsoprol, is the active principle (Keiser et al. 2000). Mel OX is hydrophilic and requires 
active uptake into the trypanosome. Studies by Carter and Fairlamb ( 1993) showed that the 
P2 nucleoside transporter mediates the uptake of Mel OX into the trypanosome  
Physiologically, the trypanosomatids use this transporter to scavenge adenosine from their 
hosts. These nucleoside transporters also mediate the uptake of diamidines (Barrett et al. 
1995) and partly pentamidine (de Koning & Jarvis 2001). The common structural feature for 
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recognition is the amidine moieties in the melamine and benzamidine moieties in these 
compounds (Fairlamb et al. 1992) (Figure 4). 
 
 
 
Figure 4: The structures of some of the molecules taken up via the P2 nucleoside 
transporter (Matovu et al. 2001c). 
 
The P2 transporter gene TbATI has been expressed in the yeast Saccharomyces cerevisiae and 
was shown to promote the uptake of melaminophenyl arsenicals (Maser et al. 1999). Further, 
melarsprol resistance has been induced in a laboratory trypanosome strain and when TbATI 
was sequenced a ten nucleotide difference between wild-type T. b. brucei and its drug-
resistant derivative was noted. Six of these mutations manifest at amino acid level. An easier 
way of identifying this set of mutation was developed by Maser et al. ( 1999) and two point 
mutations within the central fragment could be used to distinguish sensitive and resistant 
trypanosome populations. This restriction pattern has been detected in some 38/65 
melarsoprol relapse T. b. gambiense isolates from N.W. Uganda (Matovu et al. 2001b) and is 
thought to be a possible marker for melarsoprol resistant trypanosomes. 
 
These earlier studies focused on genetic markers of melarsoprol resistance and rather less 
attention has been paid to drug susceptibility testing. Only a few recently isolated populations 
have been tested (Brun et al. 2001;Matovu et al. 2001a), mainly because of the challenges in 
isolation and propagation of T. b .gambiense from patients.  
Isolation of T. b. gambiense from patients 
 
The isolation of T. b. gambiense from the patients with reportedly high relapse rate is a 
priority. As indicated earlier, high treatment failure rates have been reported in war-torn areas 
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(north western Uganda, Mbanza Kongo in northern Angola and southern Sudan), making 
isolation of the parasite logistically a difficult task. As indicacted by Brun et al., (2001) there 
are a number of approaches for isolating trypanosomes from an infected host (Figure 5). 
 
 
 
 
Figure 5: Possibilities to isolate and propagate T. b. gambiense from patient’ blood or 
cerebrospinal fluid. BF: bloodstream form; PCF: procyclic forms; Solid arrow: established 
steps; dashed arrows: hardly achievable steps.(After Brun et al.( 2001)). 
 
Cryopreservation in the field and subsequent propagation of isolates in a susceptible rodent 
might be the easiest way to isolate bloodstream forms. To begin with, the protocols for 
cryopreservation and propagation need to be improved. Using this approach, reduced 
recovery or loss of T. b. gambiense has been reported (Brun et al. 2001;Matovu et al. 2001a). 
This highlights the need to improve the current cryopreservation protocols.  
Rodent models for propagation 
The low parasitaemia in patients combined with the limited susceptibility of rodents (Aerts et 
al. 1992;Matovu et al. 2001a) complicates further propagation of the isolated parasites. The 
multimammate rat Mastomys natalensis was found to be a better model for T. b. gambiense 
than rats or mice (Mehlitz 1978) and has been extensively used for propagation studies 
(Gibson et al. 1978;Matovu et al. 2001a;Mehlitz 1979;Zillmann & Mehlitz 1979). Less 
attention has been paid to propagating the parasites to high parasitaemia that are important for 
susceptibility testing (in vitro or in vivo drug assays). The parasitaemia could be improved by 
immunosuppression using irradiation or use of a chemical immunosuppressant. Irradiated 
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mice have been used for isolation, propagation and cloning of trypanosomes, but irradiation 
facilities are not always available. In addition, the slow growth rate of T. b. gambiense means 
that it is essential for immunosuppression to be repeated. The dosages as well as the number 
of doses that do not harm the rodents need to be assessed. 
 
Drug susceptibility testing 
 
Successful isolation of T. b. gambiense strains will allow both susceptibility and genotypic 
characterization. Various in vitro tests for determining the drug sensitivity of trypanosomes to 
trypanocides have been developed (Kaminsky & Brun 1993). None of the assays is superior 
to others in all respects. The assay applied depends on the specific aim of the study, on the 
trypanosome stocks, and on the equipment available. The (H3) hypoxanthine incorporation 
assay does not require culture-adapted trypanosomes and has been shown to be suitable for T. 
b. gambiense studies (Brun et al. 1989;Brun & Kunz 1989). The test is able to distinguish 
sensitive from resistant isolates (Brun et al. 2001). In vivo drug tests are currently hindered by 
lack of a simple rodent model for T. b. gambiense. 
 
References 
 
 1.  Aerts D, Truc P, Penchenier L, Claes Y, & Le RD (1992) A kit for in vitro isolation of 
trypanosomes in the field: first trial with sleeping sickness patients in the Congo 
Republic. Trans.R.Soc.Trop.Med.Hyg. 86, 394-395. 
 2.  Apted FI (1980) Present status of chemotherapy and chemopropylaxis of human 
trypanosomiasis in the Eastern Hemisphere. Pharmacol.Ther. 11, 391-413. 
 3.  Apted F1 (1970) Clinical manifestations of sleeping sickness In: The African 
Trypanosomiases. ed. Mulligan HW (ed) . George Allen and Unwin, London, pp. 661-
683. 
 4.  Bacchi CJ, Nathan HC, Hutner SH, McCann PP, & Sjoerdsma A (1980) Polyamine 
metabolism: a potential therapeutic target in trypanosomes. Science 210, 332-334. 
 5.  Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, & Krishna S 
(2003) The trypanosomiases. Lancet 362, 1469-1480. 
 6.  Barrett MP, Zhang ZQ, Denise H, Giroud C, & Baltz T (1995) A diamidine-resistant 
Trypanosoma equiperdum clone contains a P2 purine transporter with reduced 
substrate affinity. Mol.Biochem.Parasitol. 73, 223-229. 
Introduction 
__________________________________________________________________________ 
 24 
 7.  Berberof M, Perez-Morga D, & Pays E (2001) A receptor-like flagellar pocket 
glycoprotein specific to Trypanosoma brucei gambiense. Mol.Biochem.Parasitol. 113, 
127-138. 
 8.  Berger BJ, Carter NS, & Fairlamb AH (1993) Polyamine and pentamidine metabolism 
in African trypanosomes. Acta Trop. 54, 215-224. 
 9.  Brun R, Baeriswyl S, & Kunz C (1989) In vitro drug sensitivity of Trypanosoma 
gambiense isolates. Acta Trop. 46, 369-376. 
 10.  Brun R & Kunz C (1989) In vitro drug sensitivity test for Trypanosoma brucei 
subgroup bloodstream trypomastigotes. Acta Trop. 46, 361-368. 
 11.  Brun R, Schumacher R, Schmid C, Kunz C, & Burri C (2001) The phenomenon of 
treatment failures in Human African Trypanosomiasis. Trop.Med.Int.Health 6, 906-
914. 
 12.  Burri C, Baltz T, Giroud C, Doua F, Welker HA, & Brun R (1993) Pharmacokinetic 
properties of the trypanocidal drug melarsoprol. Chemotherapy 39, 225-234. 
 13.  Burri C, Blum J, & Brun R (1995) Alternative application of melarsoprol for treatment 
of T. B. gambiense sleeping sickness. Preliminary results. Ann.Soc.Belg.Med.Trop. 75, 
65-71. 
 14.  Burri C & Keiser J (2001) Pharmacokinetic investigations in patients from northern 
Angola refractory to melarsoprol treatment. Trop.Med.Int.Health 6, 412-420. 
 15.  Burri C, Nkunku S, Merolle A, Smith T, Blum J, & Brun R (2000) Efficacy of new, 
concise schedule for melarsoprol in treatment of sleeping sickness caused by 
Trypanosoma brucei gambiense: a randomised trial. Lancet 355, 1419-1425. 
 16.  Buscher P, Lejon V, Magnus E, & Van MN (1999) Improved latex agglutination test 
for detection of antibodies in serum and cerebrospinal fluid of Trypanosoma brucei 
gambiense infected patients. Acta Trop. 73, 11-20. 
 17.  Carter NS & Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an unusual 
adenosine transporter. Nature 361, 173-176. 
 18.  Cattand P, Miezan BT, & de RP (1988) Human African trypanosomiasis: use of 
double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull.World 
Health Organ 66, 83-86. 
 19.  Chello PL & Jaffe JJ (1972) Comparative properties of trypanosomal and mammalian 
thymidine kinases. Comp Biochem.Physiol B 43, 543-562. 
 20.  de Koning HP & Jarvis SM (2001) Uptake of pentamidine in Trypanosoma brucei 
brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated 
transporter. Acta Trop. 80, 245-250. 
 21.  DeGreef C, Imberechts H, Matthyssens G, Van MN, & Hamers R (1989) A gene 
expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. 
Mol.Biochem.Parasitol. 36, 169-176. 
Introduction 
__________________________________________________________________________ 
 25 
 22.  Doua F, Miezan TW, Sanon S, Jr., Boa YF, & Baltz T (1996) The efficacy of 
pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense 
trypanosomiasis. Am.J.Trop.Med.Hyg. 55, 586-588. 
 23.  Duku, OM 1981. Human African Trypanosomiasis in the southern Sudan, Present 
situationand control measures. Proceedings of the 16th.congress of International 
Scientific Council of Trypanosomiasis Research and Control (ISCTRC) in Yaoude, 
Cameroon.  139-145p  
 24.  Dumas M & Boa F (1988) Human African trypanosomiasis. In: Microbial Disease: 
Handbook of Clinical Neurology pp.339-343. 
 25.  Enyaru JC, Odiit M, Winyi-Kaboyo R, Sebikali CG, Matovu E, Okitoi D, & Olaho-
Mukani W (1999) Evidence for the occurrence of Trypanosoma brucei rhodesiense 
sleeping sickness outside the traditional focus in south-eastern Uganda. 
Ann.Trop.Med.Parasitol. 93, 817-822. 
 26.  Enyaru, J. C. K. E. Matovu and B. Nerima 2002. Assessment of the prevalence of 
sleeping sickness caused by T. b. rhodesiense in Kamulu District, South East Uganda. 
4th. Annual Workshops.  
 27.  Fairlamb AH, Henderson GB, & Cerami A (1989) Trypanothione is the primary target 
for arsenical drugs against African trypanosomes. Proc.Natl.Acad.Sci.U.S.A 86, 2607-
2611. 
 28.  Fairlamb AH, Smith K, & Hunter KJ (1992) The interaction of arsenical drugs with 
dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and 
sensitive strains of Trypanosoma brucei brucei. Mol.Biochem.Parasitol. 53, 223-231. 
 29.  Gibson W, Mehlitz D, Lanham SM, & Godfrey DG (1978) The identification of 
Trypanosoma brucei gambiense in Liberian pigs and dogs by isoenzymes and by 
resistance to human plasma. Tropenmed.Parasitol. 29, 335-345. 
 30.  Hawking F (1978) Suramin: with special reference to onchocerciasis. 
Adv.Pharmacol.Chemother. 15, 289-322. 
 31.  Hoare C (1970)  Sytematic description of mammalian trypanosomes of Africa. In: The 
African Trypanosomiases ed. Mulligan HW. George Allen and Unwin  London ltd., 
London, pp.222-259. 
 32.  Jaffe JJ, McCormack JJ, & Meymarian E (1972) Comparative properties of 
schistosomal and filarial dihydrofolate reductases. Biochem.Pharmacol. 21, 719-731. 
 33.  Joshi PP, Shegokar VR, Powar RM, Herder S, Katti R, Salkar HR, Dani VS, Bhargava 
A, Jannin J, & Truc P (2005) Human trypanosomiasis caused by Trypanosoma evansi 
in India: the first case report. Am.J.Trop.Med.Hyg. 73, 491-495. 
 34.  Kaminsky R & Brun R (1993) In vitro assays to determine drug sensitivities of 
African trypanosomes: a review. Acta Trop. 54, 279-289. 
 35.  Kanmogne GD, Asonganyi T, & Gibson WC (1996) Detection of Trypanosoma brucei 
gambiense, in serologically positive but aparasitaemic sleeping-sickness suspects in 
Cameroon, by PCR. Ann.Trop.Med.Parasitol. 90, 475-483. 
Introduction 
__________________________________________________________________________ 
 26 
 36.  Keiser J, Ericsson O, & Burri C (2000) Investigations of the metabolites of the 
trypanocidal drug melarsoprol. Clin.Pharmacol.Ther. 67, 478-488. 
 37.  Kristensson K, Mhlanga JD, & Bentivoglio M (2002) Parasites and the brain: 
neuroinvasion, immunopathogenesis and neuronal dysfunctions. 
Curr.Top.Microbiol.Immunol. 265, 227-257. 
 38.  Kuzoe FA (1993) Current situation of African trypanosomiasis. Acta Trop. 54, 153-
162. 
 39.  Kyambadde JW, Enyaru JC, Matovu E, Odiit M, & Carasco JF (2000) Detection of 
trypanosomes in suspected sleeping sickness patients in Uganda using the polymerase 
chain reaction. Bull.World Health Organ 78, 119-124. 
 40.  Legros D, Evans S, Maiso F, Enyaru JC, & Mbulamberi D (1999) Risk factors for 
treatment failure after melarsoprol for Trypanosoma brucei gambiense 
trypanosomiasis in Uganda. Trans.R.Soc.Trop.Med.Hyg. 93, 439-442. 
 41.  Lehane MJ & Msangi AR (1991) Lectin and peritrophic membrane development in 
the gut of Glossina m.morsitans and a discussion of their role in protecting the fly 
against trypanosome infection. Med.Vet.Entomol. 5, 495-501. 
 42.  Louis JP, Moulia-Pelat JP, Jannin J, Asonganyi T, Hengy C, Trebucq A, Noutoua J, & 
Cattand P (1991) Absence of epidemiological inter-relations between HIV infection 
and African human trypanosomiasis in central Africa. Trop.Med.Parasitol. 42, 155. 
 43.  Magnus E, Vervoort T, & Van MN (1978) A card-agglutination test with stained 
trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense 
trypanosomiasis. Ann.Soc.Belg.Med.Trop. 58, 169-176. 
 44.  Maser P, Sutterlin C, Kralli A, & Kaminsky R (1999) A nucleoside transporter from 
Trypanosoma brucei involved in drug resistance. Science 285, 242-244. 
 45.  Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, & Kaminsky R (2001a) 
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. 
Trop.Med.Int.Health 6, 407-411. 
 46.  Matovu E, Geiser F, Schneider V, Maser P, Enyaru JC, Kaminsky R, Gallati S, & 
Seebeck T (2001b) Genetic variants of the TbAT1 adenosine transporter from African 
trypanosomes in relapse infections following melarsoprol therapy. 
Mol.Biochem.Parasitol. 117, 73-81. 
 47.  Matovu E, Seebeck T, Enyaru JC, & Kaminsky R (2001c) Drug resistance in 
Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana 
in cattle. Microbes.Infect. 3, 763-770. 
 48.  Meda N, Msellati P, Welffens-Ekra C, Cartoux M, Leroy V, Van de PP, & Salamon R 
(1997) [The reduction of mother-child transmission of HIV infection in developing 
countries: potential intervention strategies, obstacles to implementation and 
perspectives. The Reduction of Mother-Child Transmission of HIV Infection in Africa 
Group]. Sante 7, 115-125. 
Introduction 
__________________________________________________________________________ 
 27 
 49.  Mehlitz D (1978) [Investigations on the susceptibility of Mastomys natalensis to 
Trypanosoma (trypanozoon) brucei gambiense (author's transl)]. 
Tropenmed.Parasitol. 29, 101-107. 
 50.  Mehlitz D (1979) Trypanosome infections in domestic animals in Liberia. 
Tropenmed.Parasitol. 30, 212-219. 
 51.  Miezan TW, Meda AH, Doua F, & Cattand P (1994) [Evaluation of the parasitologic 
technics used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in 
the Ivory Coast]. Bull.Soc.Pathol.Exot. 87, 101-104. 
 52.  Molyneux DPV&DF (1996) African trypanosomiasis in man. In: Manson's Tropical 
diseases (ed.G.C. Cook) ed. WB Saunders Company ltd. London, pp.1171-1196. 
 53.  Moore A & Richer M (2001) Re-emergence of epidemic sleeping sickness in southern 
Sudan. Trop.Med.Int.Health 6, 342-347. 
 54.  Moore A, Richer M, Enrile M, Losio E, Roberts J, & Levy D (1999) Resurgence of 
sleeping sickness in Tambura County, Sudan. Am.J.Trop.Med.Hyg. 61, 315-318. 
 55.  MSF 2001. Sudan: Improving treatments of sleeping sickness and malaria amid civil.  
 56.  Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, & Kuzoe F 
(2004) The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in 
patients with late-stage T.b. gambiense sleeping sickness. Eur.J.Clin.Pharmacol. 60, 
269-278. 
 57.  Nantulya VM (1988) Immunodiagnosis of rhodesiense sleeping sickness: detection of 
circulating trypanosomal antigens in sera and cerebrospinal fluid by enzyme 
immunoassay using a monoclonal antibody. Bull.Soc.Pathol.Exot.Filiales. 81, 511-
512. 
 58.  Nantulya VM, Lindqvist KJ, Stevenson P, & Mwangi EK (1992) Application of a 
monoclonal antibody-based antigen detection enzyme-linked immunosorbent assay 
(antigen ELISA) for field diagnosis of bovine trypanosomiasis at Nguruman, Kenya. 
Ann.Trop.Med.Parasitol. 86, 225-230. 
 59.  Nieuwenhove VS, Schechter PJ, Declercq J, Bone G, Burke J, & Sjoerdsma A (1985) 
Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-
difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. 
Trans.R.Soc.Trop.Med.Hyg. 79, 692-698. 
 60.  Odiit M, Kansiime F, & Enyaru JC (1997) Duration of symptoms and case fatality of 
sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East 
Afr.Med.J. 74, 792-795. 
 61.  Penchenier L, Simo G, Grebaut P, Nkinin S, Laveissiere C, & Herder S (2000) 
Diagnosis of human trypanosomiasis, due to Trypanosoma brucei gambiense in 
central Africa, by the polymerase chain reaction. Trans.R.Soc.Trop.Med.Hyg. 94, 392-
394. 
Introduction 
__________________________________________________________________________ 
 28 
 62.  Pepin J, Ethier L, Kazadi C, Milord F, & Ryder R (1992a) The impact of human 
immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma 
brucei gambiense sleeping sickness in Nioki, Zaire. Am.J.Trop.Med.Hyg. 47, 133-140. 
 63.  Pepin J & Milord F (1994) The treatment of human African trypanosomiasis. 
Adv.Parasitol. 33, 1-47. 
 64.  Pepin J, Milord F, Meurice F, Ethier L, Loko L, & Mpia B (1992b) High-dose 
nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an 
open trial in central Zaire. Trans.R.Soc.Trop.Med.Hyg. 86, 254-256. 
 65.  Schmid C, Nkunku S, Merolle A, Vounatsou P, & Burri C (2004) Efficacy of 10-day 
melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping 
sickness. Lancet 364, 789-790. 
 66.  Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, 
Nangouma A, Doua F, Asumu PN, Simarro PP, & Burri C (2005) Effectiveness of a 
10-day melarsoprol schedule for the treatment of late-stage human African 
trypanosomiasis: confirmation from a multinational study (IMPAMEL II). 
J.Infect.Dis. 191, 1922-1931. 
 67.  SOLTYS MA (1953) Golden jubilee of the discovery of sleeping sickness in East 
Africa. East Afr.Med.J. 30, 389-392. 
 68.  Sternberg JM (2004) Human African trypanosomiasis: clinical presentation and 
immune response. Parasite Immunol. 26, 469-476. 
 69.  Van Nieuwenhove S (2000) Present strategies in the treatment of human African 
Trypanosomiasis In: Progress in Human African Trypanosomiasis, sleeping sickness 
ed. Michel Dumas BBABE pp.253-281. 
 70.  Vickerman K (1985) Developmental cycles and biology of pathogenic trypanosomes. 
Br.Med.Bull. 41, 105-114. 
 71.  Welburn SC, Fevre EM, Coleman PG, Odiit M, & Maudlin I (2001) Sleeping 
sickness: a tale of two diseases. Trends Parasitol. 17, 19-24. 
 72.  Wellde BT, Chumo DA, Hockmeyer WT, Reardon MJ, Esser K, Schoenbechler MJ, & 
Olando J (1989a) Sleeping sickness in the Lambwe Valley in 1978. 
Ann.Trop.Med.Parasitol. 83 Suppl 1, 21-27. 
 73.  Wellde BT, Chumo DA, Reardon MJ, Abinya A, Wanyama L, Dola S, Mbwabi D, 
Smith DH, & Siongok TA (1989b) Treatment of Rhodesian sleeping sickness in 
Kenya. Ann.Trop.Med.Parasitol. 83 Suppl 1, 99-109. 
 74.  Wellde BT, Chumo DA, Reardon MJ, Nawiri J, Olando J, Wanyama L, Awala J, 
Koech D, Siongok TA, & Sabwa C (1989c) Diagnosis of Rhodesian sleeping sickness 
in the Lambwe Valley (1980-1984). Ann.Trop.Med.Parasitol. 83 Suppl 1, 63-71. 
 75.  WH0 2004. World Health Report.  
 76.  WHO 1998a. African trypanosomiasis Control. Control of Tropical Diseases (CTD). 
Geneva.  
Introduction 
__________________________________________________________________________ 
 29 
 77.  WHO 1998b. African Trypanosomiasis: Control and surveillance. Report of WHO 
Expert Committee. WHO Tech. Rep. Ser. No. 881 
 78.  Williamson J, Macadam RF, & Dixon H (1975) Drug-induced lesions in trypanosome 
fine structure: a guide to modes of trypanocidal action. Biochem.Pharmacol. 24, 147-
151. 
 79.  Willson M, Callens M, Kuntz DA, Perie J, & Opperdoes FR (1993) Synthesis and 
activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma 
brucei. Mol.Biochem.Parasitol. 59, 201-210. 
 80.  Woo PT (1970) The haematocrit centrifuge technique for the diagnosis of African 
trypanosomiasis. Acta Trop. 27, 384-386. 
 81.  Zillmann U & Mehlitz D (1979) The natural occurrence of Trypanozoon in domestic 
chicken in the Ivory Coast. Tropenmed.Parasitol. 30, 244-248. 
Goals and Objectives 
___________________________________________________________________________ 
 30 
 
CHAPTER 2:  Goals and objectives 
 
 
Goal 
The goal of the studies presented in this thesis was to determine the role of melarsoprol 
resistant trypanosomes in the high treatment failures rates in HAT patients in south Sudan.  
 
Objectives 
 
The project had the following objectives: 
 
1. To improve the protocol for cryopreservation of bloodstream forms T. b. 
gambiense from HAT patients.   
2. To isolate and establish a cyrobank of well characterized T. b. gambiense from 
south Sudan. The isolates would in future be available to World Health 
Organization (WHO) and other scientists. 
3. To improve the propagation of T. b. gambiense field isolates in laboratory rodents.  
4. To determine the sensitivities of the isolated trypanosomes to trypanocides 
melarsoprol, melarsen oxide, pentamidine, diminazene, DB 75 and nifurtimox. 
5. To characterize the P2 nucleosides transporter gene (TbATI) in the isolated 
trypanosomes 
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Abstract 
 
There have been major advances in the formulation of cryomedia for spermatozoa owing to 
their economic importance. In this study, the suitability of the commercial cryomedium 
Triladyl developed for bull semen was evaluated for the cryopreservation of Trypanosoma 
brucei gambiense. Cryopreservation efficacy was determined by direct counting of motile 
trypanosomes and by viability assessment using in vitro and in vivo methods. Culture medium 
containing 10% glycerol was used as the control. Trypanosomes cryopreserved in Triladyl 
demonstrated a higher in vitro viability than those in culture medium with 10% glycerol. 
Similar results were obtained in vivo in immunosuppressed Mastomys natalensis. 
Trypanosomes cryopreserved in Triladyl showed better growth characteristics than those in 
culture medium with glycerol. It can be concluded that the use of Triladyl in the 
cryopreservation of T. b. gambiense leads to a better survival of the trypanosomes which 
could lead to an improved isolation of T. b. gambiense from sleeping sickness patients. 
 
Key words: Trypanosoma brucei gambiense; cryopreservation; Triladyl; glycerol 
 
Introduction 
 
Characterisation of Trypanosoma brucei gambiense from human African trypanosomosis 
(HAT) patients, especially from those showing a relapse after treatment, is of high priority, 
e.g. to determine the drug sensitivity profile (Brun et al., 2001). The difficulty of obtaining 
isolated parasites, however, hinders such studies. Isolation of bloodstream forms has mainly 
been achieved by inoculating infected blood samples from patients into laboratory rodents. 
The low parasitaemia in patients and the limited susceptibility of rodents complicates the 
process (Dukes et al., 1989; Aerts et al., 1992; Matovu et al., 2001). The development of a kit 
for in vitro isolation (KIVI) of procyclic forms (Truc et al., 1992; Aerts et al., 1992) enhanced 
isoenzyme characterization and DNA characterization. The KIVI kit however, did not help to 
study drug sensitivity since the required assays depend on bloodstream forms. 
 
Several possibilities for isolating T. b. gambiense from patients exist: isolation into in vitro 
culture, inoculation of susceptible animals, and cryopreservation of infected blood samples. 
Isolation of bloodstream forms into culture under field conditions is almost impossible 
because most cultures will be found to be contaminated by bacteria and fungi (Maser et al., 
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2002). Inoculation into susceptible rodents is usually not feasible since the animals have to be 
transported to the patients far from a laboratory. Cryopreservation of infected blood samples 
in liquid nitrogen (-196oC) in the field and subsequent propagation in susceptible rodents in 
the laboratory would provide an ideal way to isolate T. b. gambiense strains from patients. 
 
The current methods for cryopreservation for trypanosomes were developed almost 50 years 
ago with minor improvements for field isolation by Dar et al. (1972). However, reduced 
recovery or loss of infectivity of T. b. gambiense following cryopreservation has been 
observed (Brun et al., 2001; Matovu et al., 2001; J. Enyaru. personal communication). Studies 
using media developed for cryopreservation of human spermatozoa indicated that these are 
superior to the standard media (J. Atouguia, personal communication). Cryomedia for human 
sperms are, however, very expensive. Triladyl, a medium developed for bull semen, is much 
more economical in use. In the present study we investigated the suitability of Triladyl for the 
cryopreservation of T. b. gambiense bloodstream forms. 
 
Materials and methods 
Media used for cryopreservation 
 
Triladyl is produced by MiniTüB GmbH & CO. KG (Tiefenbach, Germany). It contains 8% 
glycerol, 20% egg yolk, Tris buffer, citric acid, fructose and antibiotics (tylosin 5mg/l, 
gentamicin 25mg/l, spectinomycin 30mg/l, and lincomycin 15mg/l in distilled water). Triladyl 
was stored at 4oC or frozen at -20°C. Control cells were frozen in culture medium (see below) 
containing 10% glycerol. 
 
Trypanosome strains 
 
Trypanosoma b. gambiense DAL 1402 was obtained from the cryobank of the “Project de 
Recherches Cliniques Sur la Trypanosomiase,” in Daloa. It was isolated in1990 from a human 
patient in Cote d’Ivoire. Trypanosoma b. gambiense KETRI 2565 was obtained from the 
cryobank of the Trypanosomiasis Research Centre (TRC, formerly KETRI), Kenya. It was 
isolated in 1982 from a patient in Yambio, South Sudan. 
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Cultivation and cryopreservation  
 
The trypanosome strain (T. b. gambiense DAL 1402) was cultivated in axenic culture in a 
mixture of RPMI 1640 and MEM with Earle’s salts (1:1), supplemented with 5% heat-
inactivated fetal bovine serum (FBS), 12% human serum from the local blood bank, 0.05mM 
bathocuproine sulphonate, 0.12mM mercaptoethanol, 1mM sodium pyruvate, 2mM L-
glutamine, 1.5mM L-cysteine and 0.2mM hypoxanthine. Trypanosomes from axenic culture 
were centrifuged at 1200g for 10 minutes and re-suspended in fresh medium. The 
trypanosome concentration was determined by direct counting in a haemocytometer.  
 
Tubes containing 900µl cryomedia were cooled in ice and 100 µl of trypanosome suspension 
were added. Various trypanosome concentrations ranging from 10 to 2 x 106 trypanosomes/ml 
were prepared. Aliquots (0.5ml) were transferred into cryo-ampoules (NUNC®, 1.8ml). The 
ampoules were cooled slowly at a rate of approximately -2oC /minute in the vapour phase of a 
liquid nitrogen container and then immersed in liquid nitrogen at -196oC. After at least five 
days of storage, the stabilates were thawed rapidly at 37oC in a water bath to determine 
viability.  
 
Upon thawing, the trypanosomes were centrifuged and re-suspended in culture medium. The 
recovery was assessed by counting the motile trypanosomes. Briefly, 10µl of thawed 
trypanosome suspension was transferred to a haemocytometer, motile trypanosomes counted, 
and the result expressed as a percentage of the original number of trypanosomes 
cryopreserved. When the initial concentration was less than 104 trypanosomes/ml, the 
trypanosomes could not be counted directly, but were seeded into wells of a 24-well culture 
plate and examined daily under a microscope. After four days of incubation, the concentration 
of trypanosomes was assessed by counting in a haemocytometer.  
 
Infectivity of cryopreserved trypanosomes in immunosuppressed M. natalensis  
 
Mastomys natalensis from a breeding colony at the Trypanosomiasis Research Centre (TRC, 
formerly KETRI), Kenya, were immunosuppressed by administration of cyclophosphamide 
(200 mg/kg bw intraperitoneally (ip)) one day prior to infection. A donor M. natalensis was 
inoculated ip with 0.5ml of thawed T. b. gambiense KETRI 2565 suspension. The rodent was 
sacrificed 7 days post-infection when parasitaemia was 5-10 trypanosomes/field in a wet 
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smear of tail blood. Trypanosomes were separated from blood cells by differential 
centrifugation and the concentration of trypanosomes estimated in a haemocytometer.  
 
Concentrations of 20, 200 and 2 x 104 trypanosomes/ml were prepared in control medium 
containing 10% glycerol or in Triladyl and cryopreserved as described above. After five days 
of storage, the stabilates were thawed and the contents of each ampoule inoculated ip into two 
immunosuppressed M. natalensis. A control group of four rodents for each inoculum dose 
received trypanosomes that were not cryopreserved. Parasitaemia was monitored from the 
third day on and every other day for 20 days by the haematocrit centrifugation technique and 
by examination of wet smears from tail blood (Herbert and Lumsden, 1976). 
 
Optimum concentration of Triladyl for cryopreservation  
 
Trypanosomes (2.7 x 105/ml) were cryopreserved at varying concentrations of Triladyl (20, 
30, 40 50, 60, 70, 80 and 90% Triladyl in culture medium; see 2.3.). After five days in liquid 
nitrogen the stabilates were thawed and recovery assessed by counting the motile 
trypanosomes in a Neubauer haemocytometer. The percentage recovery of trypanosomes was 
calculated. 
 
Results 
 
Recovery and in vitro viability of trypanosomes after cryopreservation 
 
Survival after cryopreservation was higher in Triladyl (73-50%) than in medium containing 
10% glycerol (30%) (Figure 1). At low trypanosomes concentrations (<104) direct counting 
was not possible. Viability was assessed by culturing the thawed samples. The growth of 
trypanosomes frozen in medium containing 10% glycerol was lower than that of those frozen 
in Triladyl. In some instances, motile trypanosomes could be seen after cryopreservation but 
could not be propagated during subsequent in vitro cultivation. When 5 
trypanosomes/ampoule (10 trypanosomes/ml) or fewer were cryopreserved, no motile 
trypanosomes could be observed either immediately after thawing or during the following 14 
days of cultivation. 
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Infectivity of cryopreserved trypanosomes for M. natalensis  
 
The inoculated number of trypanosomes influenced the parasitaemia pattern in 
immunosuppressed M. natalensis (prepatent period, duration to peak parasitaemia, and 
parasite density at peak parasitaemia). For example, a high inoculum led to a shorter prepatent 
period and a shorter duration to peak parasitaemia than a low inoculum. Differences in 
parasitaemia pattern were noted between the groups inoculated with cryopreserved and non-
cryopreserved trypanosomes. At all concentrations tested, cryopreservation resulted in a 
pattern of parasitaemia corresponding to a smaller inoculum of viable cells: longer prepatent 
period, longer duration to peak parasitaemia and lower density at peak parasitaemia. This 
reduction in growth characteristics was more pronounced in samples frozen in the control 
medium than in those frozen in Triladyl (Table 1).  
 
Optimum concentration of Triladyl for cryopreservation  
 
Trypanosomes could be recovered after cryopreservation at all the concentrations of Triladyl 
tested. At low concentrations of Triladyl the percentage recovery was however less than 30%. 
At concentrations of Triladyl between 40 and 90%, recovery rates between 50 and 63% could 
be found. The differences in the percentage recovery between 40, 50, 60, 70, 80 and 90% 
Triladyl were not significant. 
 
Discussion 
 
The present study has demonstrated successful cryopreservation of trypanosomes in a 
medium used for cryopreservation of bull semen. A larger proportion of trypanosomes 
survived cryopreservation in Triladyl than in glycerol. In addition, cryopreservation in 
Triladyl resulted in higher in vitro viability and in vivo infectivity than those cryopreserved in 
10% glycerol.  
 
The survival rate of eukaryotic cells after cryopreservation depends on many factors such as 
the cryopreservation medium, volume of sample, freezing rate and thawing conditions 
(reviewed by Diamond 1995). Cryopreservation may also select for subpopulations of 
parasites with distinct characteristics in virulence or drug sensitivity. Therefore, a high 
survival rate is considered desirable for maintaining the population’s heterogeneity and to 
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prevent a genetic drift. An ideal cryopreservation medium should hence recover a high 
proportion of the frozen trypanosomes. The results of this study indicate that Triladyl is better 
as compared to the control culture medium with 10% glycerol. Triladyl contains besides 
glycerol a second membrane protecting component namely egg yolk (20%). Egg yolk acts as 
a buffer but also coats the cells thereby protecting the lipoproteins in the cell membrane 
during freezing and thawing. The optimum concentration of Triladyl was found to be between 
40% and 90%. 
 
Apart from high survival rate, the subsequent viability of the preserved parasite is essential. It 
is important to remember that blood samples from some T. b. gambiense patients contain only 
10-50 trypanosomes/ml of blood and in those cases, the high survival rate is crucial for the 
subsequent propagation. Viability can be determined by transferring the thawed trypanosomes 
to an in vitro culture system or injecting them to susceptible rodents. In vitro propagation of 
trypanosomes is frequently hindered by contamination (Maser et al., 2002) and advantages of 
cryomedia that contain antibiotics, such as Triladyl, have been shown in field isolation of 
trypanosomes (Dukes et al., 1989; Truc et al., 2004). Nevertheless, maintenance of 
bloodstream form requires a well equipped laboratory that may not be available in most field 
sites.  
 
According to Brun et al. (2001), cryopreservation of infected blood samples and subsequent 
propagation in susceptible rodents is the easiest method to isolate T. b. gambiense from 
patients. In the current study we evaluated this procedure. Generally, T. b. gambiense cannot 
be propagated in normal mice and immunosuppressed M. natalensis were used. Our results 
indicate that parasites that were frozen in Triladyl developed more reproducibly and had 
better infectivity than those frozen in glycerol. Alternatively, severe combined 
immunodeficient (SCID) mice could be used for propagation. The SCID mice are highly 
susceptible to T. b. gambiense (Inoue et al., 1998).  
 
This study showed that Triladyl is a better cryopreservation medium than standard culture 
medium with 10% glycerol resulting in a higher survival rate of the frozen trypanosomes. It 
remains to be demonstrated in the field that this new cryomedium leads to an improved 
isolation of T. b. gambiense from HAT patients in endemic areas.  
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Figure 1: Survival rates of T. b. gambiense after cryopreservation in Triladyl and 
glycerol. Various concentrations of T. b. gambiense DAL 1402 were cryopreserved in 
Triladyl (90%) (■) and glycerol (10%) (□). After at least five days of storage, the samples 
were thawed and recovery assessed by counting the motile trypanosomes. 
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Number of 
trypanosomes 
frozen in 
500µl 
 
Cryomedium 
 
Cryo-
preservation 
No of animals 
developing 
parasitaemia/ 
No injected  
Pre-patent 
period, 
days 
First peak 
parasitaemia, 
No. tryp/ml  
(day) 
 No 3/4 5 7.9 x 106(10) 
Triladyl  Yes 1/2 14 2.5 x 105(19) 
10 
Glycerol Yes 0/2 -. -. 
 No 4/4 3 7.9 x 106 (9) 
Triladyl  Yes 1/2 7 2.5 x 106 (16) 
100 
Glycerol Yes 1/2 17 2.5 x 106 (19) 
 No 4/4 3 3.1 x 107 (7) 
Triladyl Yes 2/2 5 2.5 x 106 (7) 
10000 
Glycerol Yes 1/2 7 2.0 x 106 (21) 
      
 
 
Table 1: Infectivity of cryopreserved bloodstream forms of T. b. gambiense KETRI 2565 
for M. natalensis frozen in different media. The trypanosomes were cryopreserved in 90% 
Triladyl or in control culture medium with 10% glycerol, and stored for five days in liquid 
nitrogen. Parasitaemia was monitored every other day for 20 days using the haematocrit 
centrifugation method and the method of Herbert and Lumsden (1976). 
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Introduction 
 
Human African Trypanosomosis (HAT), also known as sleeping sickness, is caused by 
Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. The disease is 
endemic in 36 countries in sub-Saharan Africa. Re-emergence of epidemic sleeping sickness 
has been described by several authors (Cattand et al. 2001;Moore & Richer 2001;Van 
Nieuwenhove et al. 2001). T. b. gambiense epidemics have mainly been reported from the 
southern and south western parts of Sudan near the border of Uganda, the Democratic 
Republic of Congo (DRC) and the Central African Republic (CAR). Control of HAT in 
Sudan is largely dependent on programs initiated by international and Non-governmental 
organisations (NGO’s). However, civil strife (since 1959), political and financial problems 
frequently disrupted the control program (Moore & Richer 2001). A recent resurgence of 
HAT within several foci has resulted in a prevalence exceeding 5%. Ibba in Maridi County in 
the province of Western Equatoria in southern Sudan was found to be the most active focus 
with a prevalence of 29% (Moore & Richer 2001). In 1997, Médecins Sans Frontièrs Holland 
(MSF-H) started a HAT control program in this county which was handed over to MSF-F 
(France) in 1999. 
 
In the frame of a study with the ‘Eastern Africa Network for Trypanosomosis’ (EANETT) we 
visited the program of MSF-F in southern Sudan in March/April 2003. The aim was to isolate 
trypanosomes from HAT patients in order to determine genotypic and phenotypic 
characteristics. In this report, we discuss aspects affecting HAT control in southern Sudan, 
our experiences and problems encountered in the field. 
 
Approval of study protocol was given by the World Health Organisation (WHO) and the 
Sudan People's Liberation Army (SPLA). Patients included in the study had to give a written 
or a thumb-printed consent by themselves or by their attendant(s). Information on the 
patient’s history was obtained from the patients (or their attendants) or was extracted from 
hospital records. Questionnaire on age, sex, residence (sub-county, village), whether there 
were other relatives in hospital, concomitant diseases, and treatment regimes were collected. 
Direct observation on homesteads set up, vegetation and human activities were recorded as 
well. 
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The study site 
MSF-France maintained a laboratory in the public hospital in Maridi and a hospital for second 
stage patients in Ibba. Since April 2002, a hospital for first stage patients was built in Kotobi, 
Mundri county. Most patients diagnosed were from Mundri, indicating that this county was 
more active than Maridi county (MSF-F personal communication; see Fig. 1) which might 
necessitate the expansion of the HAT hospital in Kotobi for the treatment of the second stage 
disease. 
 
There were no tarmac roads and the earth roads had to be constructed by the local 
communities. The distance from Ibba to Kotobi for example is approximately 150 km, but the 
average time required by a four-wheel drive vehicle was about 5 hours (see Figure 2). Some 
villages in Mundri County were too far away and could not be accessed by MSF because of 
the lack of a proper road system. 
 
The ecological characteristics of the two Counties appeared favourable for tsetse fly breeding 
and tsetse-human contact. The main vectors for T. b. gambiense are the riverine flies of the 
palpalis group. A tsetse control programme does not exist. The reasons may be found in 
financial, personnel and logistic limitations. The region around Ibba was mainly of equatorial 
climate with bush vegetation and rain forest, whereas the area visited in Kotobi presented 
rather a savannah-like climate, which was hotter and more humid than in Ibba. The 
homesteads of the residents were scattered and only partially cleared. The regional economy 
was mainly based on subsistence farming, where a significantly increased risk of infection 
was associated in earlier studies (Moore et al. 1999). 
 
The inhabitants spent much of their time in the forests (farming, hunting, honey, and termite 
harvesting) and along the rivers (bathing, fetching water, fishing, washing). The type of 
human settlement might imply that communities were exposed to tsetse fly bites within the 
homesteads. Some of the patients lived in the same compound and were related. This area 
seems to be highly infested by tsetse flies and humans are exposed to tsetse flies everywhere. 
In Tambura county similar observations were made (Joja & Okoli 2001;Noireau et al. 1989) 
and exposure in the homesteads might explain the familial aggregation noted in this study. 
 
Little is known about animal reservoirs of T. b. gambiense and their impact to epidemic foci 
(Herder et al. 2002) . It was demonstrated that domestic animals such as pigs, dogs, goats, and 
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chickens can act as reservoirs (Njiokou et al. 2004;Noireau et al. 1989). As an alternative 
source of blood, pigs in homesteads can even reduce the transmission of sleeping sickness to 
humans (Meda et al. 1993). Domestic animals at the visited sites included chicken and goats, 
and in Mundri cattle, were mainly owned by the nomadic tribes. Studies done to date show 
that animals might play an epidemiologically significant role as reservoir for T. b. gambiense 
trypanosomosis, but more studies need to be done (Herder et al. 2002;Noireau et al. 1989). A 
method to detect T. b. gambiense in various reservoir species with a high specificity is needed 
to conduct a large scale study on the distribution of T. b. gambiense in reservoir animals. 
CATT (card agglutination test for trypanosomosis) is not specific enough (Noireau et al. 
1991) to detect T. b. gambiense from animal blood samples. 
 
HAT screening in Western Equatorial 
 
MSF-F aimed at reducing HAT through case detection and treatment, since humans are 
suggested to be the main reservoir of T. b. gambiense. The strategy to treat HAT patients as 
early as possible, lowers the disease incidence and human mortality (Moore & Richer 2001) . 
People were screened either passively in the hospital, or actively by a mobile team which 
moved from one village to another (See Figure 3). The screening was done in public or social 
places (such as markets or churches), reaching people during their daily activities. Since 
public transport is inexistent, people had to walk to the screening centres. However, not 
everyone reporting at screening sites agreed to be tested. In certain places, active screening 
was hampered by poor turn-up despite prior information and sensitisation campaigns to the 
communities. At one place, screening had to be terminated because of a minor fight among 
soldiers in the neighbouring village. Apart from these constraints, active screening requires a 
lot of resources (vehicles, personnel, equipment). This limitation determines the number of 
such campaigns that can be carried out in a given time period. Similar constraints might 
explain why most HAT patients treated at the NGO hospitals were identified via passive 
screening instead of active. It is inevitable that undiagnosed cases are still present within 
villages, presenting a danger for the healthy inhabitants. 
 
In 2002, approximately 70% of the HAT patients treated in the Ibba hospital treated were in 
the 2nd stage of the disease (MSF-F, unpublished). This fact indicates that even after several 
years of active and passive screening by MSF-F, the number of second stage cases was still 
exceeding that of first stage cases. In other parts of southern Sudan, first stage cases made up 
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a total of 60% (Moore & Richer 2001). An effective control system should detect more first 
stage patients than second stage patients and this would make treatment safer, cheaper, and 
faster. 
The diagnosis-scheme (recommended by WHO) included CATT-test (Magnus et al. 1978) 
and microscopic examination of lymph node aspirates and venous blood using the micro-
haematocrit (mHCT) method. Lumbar puncture was carried out on all patients positive in any 
of the diagnostic tests to classify the stage of the disease. Staging was done by examining the 
cerebrospinal fluid (CSF) for trypanosomes (2nd stage if positive) and by counting white 
blood cells (WBC) according to WHO classification (1st stage ≤ 5cells/µl; 2nd stage > 
5cells/µl in CSF). Patients with second stage disease had WBC counts in CSF ranging from 5 
to 1541 cells/µl. 
 
As reported by Moore et al. (2001), the serological CATT diagnosis has a higher sensitivity 
than direct parasite detection methods. CATT is the primary method used for the diagnosis of 
both stages of T. b. gambiense. However, during this study it gave false negative results in 
two parasite-positive patients implying that patients with low, undetectable parasitemia might 
have been misdiagnosed. One of the two patients had been tested with CATT four times over 
2 years and was found to be negative. At the time of this study, trypanosomes were detected 
only in the CSF and the patient was in coma, but still CATT-negative. 
 
The CATT is using the LiTat 1.3 antigen (Magnus et al. 1978). The T. b. gambiense serotypes 
that do not express this antigen were thought to have a limited distribution. Similar false 
negative results with CATT diagnosis have been reported in north western Uganda (Enyaru et 
al. 1998;Matovu et al. 2003) and may be attributed to T. b. gambiense strains missing the 
LiTat 1.3 antigen gene. 
 
Patients and treatment 
  
Fifty-two HAT patients from Mundri (48), Maridi (2), Yambio (1), and Juba (1) were 
included in this study (Fig 1). The age of the patients ranged from 3 months to 62 years. Most 
patients (92%) were less than 40 years old. One patient was in first stage of the disease; all 
others in the second stage. Trypanosomes in CSF were detected in only 8 of the patients 
(Table 1). Melarsoprol has been the first-line drug for treatment of the 2nd stage of T. b. 
gambiense infection since 1959. The high rates of treatment failures within a short period  
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(Moore & Richer 2001) and the high death rate following melarsoprol treatment (MSF, 
personal communication) led to a change of the treatment regime from melarsoprol to 
eflornithine (difluoromethylornithine) in 2001. This change resulted in a 3-fold increase in the 
number of patients seeking treatment and a decrease in drug related fatalities from 8% with 
melarsoprol to 1.6% with eflornithine (Chappuis et al. 2005). Figure 4 (c and d), shows the 
patients under treatment. 
 
Treatment failures following eflornithine treatment were noted several times in the Ibba SS 
hospital, although eflornithine had been used for the last 2 years only. Seven patients (of the 
52) relapsed after treatment: Three patients relapsed after pentamidine treatment (1st stage) 
and 4 after eflornithine treatment. Relapses after pentamidine treatment might have been due 
to misdiagnosed early 2nd stage disease. These patients were subsequently treated with 
eflornithine. The four eflornithine-relapse patients were re-treated with a combination of 
melarsoprol (1.2mg/kg/day iv for 10 days) and nifurtimox (15mg/kg/day divided into three 
doses for 10 days). Whether the treatment failures were due to drug resistant trypanosome is 
still under investigation (Brun et al. 2001). Treatment failures might be due to wrong drug 
application, individual differences in the pharmacokinetics of the drug, misclassification of 
the stage, interference with food (MSF-F personal communication), trypanosomes at body 
niches that are not accessible to the drug, or resistant trypanosome strains (WHO 1998). 
 
The treated patients were not examined for trypanosomes immediately after completion of 
treatment. When they were checked 6 months to 2 years after treatment and classified as 
relapse patients, a re-infection could not be ruled out in a region of high endemicity. The 
WHO considers trypanosome-positive patients within 2 years after treatment as relapse cases. 
Many HAT patients had other concurrent infections, such as malaria (21/52), filariasis (loa 
loa 23/52 and onchocerciasis 2/52), and gastro intestinal protozoa (Giardia and Entamoemba 
histolytica 2/52). Loa loa was left untreated, malaria was treated before, and the other 
infections were treated after completion of the HAT treatment regime. 
 
High levels of treatment failures to common anti-malarials (such as chloroquine, sulfadoxine-
primethamine, artemisinins) have also been noted. Therefore, Coartem® (Artemether and 
lumefantrine, Novartis, Switzerland) was the first line drug in the NGO hospitals. Malaria 
treatment started one day before the HAT therapy and was administered for 3 days. The 
patients having malaria and HAT were treated with Coartem® and eflornithine 
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simultaneously. Furthermore, little is known about the interaction between Plasmodium 
falciparum and T. b. brucei, and about the resulting immune responses. 
 
The treatment failures noted with different drugs and in different diseases (malaria and HAT) 
might be due to host-related factors including individual variation in the drug 
pharmacokinetics and (the patients’) immune responses. For an effective cure a competent 
immune system is necessary but malaria and HAT both lead to immunosuppression. Pepin et 
al.(1992) found that human immunodeficiency virus (HIV) co-infected HAT patients 
responded less to eflornithine treatment than seronegative individuals. Studies to establish the 
causes of treatment failure at patient’s level as well as the drug sensitivity of infecting 
parasites should be a priority (Brun et al. 2001).  
 
Lastly, a control of HAT by chemotherapy has been the major control strategy in southern 
Sudan since the disease was documented, but a combination with vector control might be the 
optimal strategy. The aim of this combined approach would be to lower the density of tsetse 
flies and the prevalence in the human population simultaneously, thus reducing the rate of 
transmission. This approach was successfully introduced in Tambura county (Joja & Okoli 
2001). 
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Figure 2: The communication systems in south Sudan. There are two airstrips for the region in 
Yambio and Maridi county. The pictures shows; the airstrip at Maridi county after a heavy 
down pour (a) and  a section of temporary roads used within the region (b) 
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Figure 3: Shows the active screening set-up (a & b) used by the mobile team. The set-up 
allowed all HAT diagnosis in the field. Also lumbar punctures were done in the field and not 
repeated in the hospitals. The laboratories in the hospitals (c) were adequately equipped for 
further diagnosis (malaria tests were done in the hospitals). The bomb shelters (d) were also 
available in the hospitals and staff quarters. 
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Figure 4: The two HAT treatment centres in Ibba (a) and Kotobi (b). On admission, each 
patient has to have one or two attendants (usually close relatives) to cook and take care. As 
such the number of people in the wards can be very high. The wards are general (the patients 
are not separated by age or sex) and a bed is allocated only to the patient. The wards are well 
organised and high hygiene measures maintained. (c) Shows a ward in Ibba centre with the 
second stage patients receiving eflorintihtine. (d) Shows a baby (less than 3 months) who was 
at second stage while the mother was at the first stage, a possible case of trans-placental 
transmission. 
 
 
 
d
ba
c
Sleeping sickness in south Sudan: An outlook  
___________________________________________________________________________ 
 52 
 
          
Blood 3 
  
CSF5  
    
No. Isolation no S. C.1 Age2 Sex tryps. CATT Lym4 tryps. cells treatment other parasites 
1 AAK0303047B  Mundri 11 male neg. n.d. n.d. neg 52 Nif./Mel   
2 AAK0303048B Lozoh 20 male +++ n.d n.d. neg 58 Nif./Mel Loa Loa 
3 AAK0303039B Mundri 24 female neg. n.d. Neg neg 93 Nif./Mel Loa Loa 
4 AAI0304009B Kediba 46 male n.d. n.d. n.d. pos 327 Nif./Mel Loa Loa 
5 AAK0303047B Mundri 18 male + n.d n.d. neg 201 DFMO Malaria 
6 AAI0304020B Lozoh 32 female neg n.d. n.d. neg 31 DFMO malaria/ Loa Loa 
7 AAK0303031B Kozumbi 62 male neg. n.d. n.d. neg 35 DFMO Malaria 
8 AAK0303029B Kotobi <1 femal n.d. pos n.d. Neg 156 DFMO   
9 BB0303016B Lozoh 6 male + pos n.d. Pos 128 DFMO   
10 AAK0303043B Mundri 6 male +++ neg Pos Neg 9 DFMO Worms 
11 AAK0303045B Mundri 12 male n.d. pos n.d. Neg 8 DFMO Malaria 
12 AAK0303059B Lozoh 9 female n.d pos Neg Neg 7 DFMO malaria/Giardia/Trichomonas 
13 AAI0303037B Mundri 12 female n.d. pos Pos Neg 49 DFMO malaria/Giardia/Trichomonas 
14 AAI0303030B Lozoh 12 female n.d. n.d. Pos Neg 8 DFMO malaria/ E. histolytica 
15 AAK0303044B Mundri 12 female + n.d. Pos Neg 20 DFMO malaria 
16 AAK0303054B Lazoh 25 male ++ pos n.d. Neg 22 DFMO   
17 AAK0303035B Kotobi 40 female n.d. n.d. Pos Pos 403 DFMO   
18 AAK0303032B Lozoh 22 female +++ pos n.d. Pos 783 DFMO   
19 AAK030310B Mundri 27 male +++ pos Pos Neg 61 DFMO worms/ E. hystolytica 
20 BBK0304001B Lazoh 38 male +++ n.d. Pos Neg 8 DFMO   
21 AAK0303052B Lozoh 31 female +++ pos n.d. Neg 24 DFMO malaria 
22 AAK0303042B Mundri 20 male n.d. n.d. Pos Neg 10 DFMO malaria 
23 AAK0303040B Lozoh 16 female ++ pos n.d. Neg 15 DFMO malaria 
24 AAK0303046B Mundri 37 female + n.d. Pos Neg 25 DFMO malaria 
25 AAK0303030B Kotobi 21 female ++ pos n.d. Neg 4 Pent. malaria 
26 AAK0303027B Kediba 41 female + pos n.d. Neg 20 DFMO Loa Loa 
27 AAK0303038B Mundri 20 male + pos n.d Neg 7 DFMO malaria 
28 BBK0304011B Kediba 34 male + pos n.d. Neg 31 DFMO Loa Loa 
29 AAK0303051B Mundri 23 male n.d. pos n.d. Neg 50 DFMO   
30 AAKO303022B Kediba 25 male ++ pos n.d. Neg 8 DFMO malaria/ Loa Loa 
31 AAK0303028B Mundri 25 male ++ pos n.d. Neg 6 DFMO Loa Loa 
32 AAI0304006B Lozoh 23 male ++ pos Pos Pos 1541 DFMO   
33 AAI0304007B Lozoh 21 male n.d. pos Neg Neg 15 DFMO Loa Loa 
34 AAI0304008B Lozoh 19 female n.d. pos Pos Neg 8 DFMO Loa Loa 
35 AAI0304010B Mundri 18 female ++ n.d. Pos Neg 6 DFMO malaria 
36 AAI0304011B Kediba 19 male + pos Pos Pos 167 DFMO malaria/ Loa Loa 
37 AAI0304012B Lozoh 8 female + pos Pos Neg 16 DFMO Loa Loa 
38 AAI0304013B Lozoh 15 female + pos Pos Neg 10 DFMO malaria/ Loa Loa 
39 AAI0304014B Lozoh 27 female + pos Pos Neg 10 DFMO Loa Loa 
40 AAI0304015B Lozoh 12 male + pos Pos Neg 104 DFMO malaria 
41 AAI0304016B Lozoh 37 female neg pos Pos Neg 10 DFMO malaria 
42 AAI0304017B Lozoh 62 male neg pos Pos Neg 49 DFMO Loa Loa 
43 AAI0304018B Tatigiri 32 female + pos Pos Pos 413 DFMO Loa Loa 
44 AAI0304019B Lozoh 10 male ++ pos Pos Neg 17 DFMO Loa Loa 
45 AAI0304021B Lozoh 23 female ++ pos Pos Neg 45 DFMO Loa Loa 
46 AAI0304022B Lozoh 9 female +++ pos Pos Neg 8 DFMO Loa Loa 
47 AAI0304023B Lozoh 32 female neg pos Pos Neg 11 DFMO Loa Loa 
48 AAI0304024B Lozoh 20 male n.d. pos Pos Pos 625 DFMO malaria/ Loa Loa 
49 AAI0304025B Ibba 32 female neg n.d. Pos Pos 779 DFMO Loa Loa 
50 AAI0304026B Yambio 25 female n.d. neg n.d. Pos 309 DFMO   
51 AAI0304027B Ibba 28 female n.d. n.d. Pos Neg 11 DFMO Loa Loa 
52 AA0304028B Mundri 51 male n.d. Pos n.d. n.d. - DFMO   
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Table 1: Isolates of all patients examined. Patients 1 to 7 are relapse cases. Grey-marked 
isolation numbers indicate successful propagation in laboratory rodents followed by 
cryopreservation. DFMO = eflornithine; 1 Sub County; 2 age in years; 3 blood examination by 
hematocrit centrifugation technique (= tryps.) to estimate parasitemia (+ as 1-5, ++ as 6-15 
and +++ as >15 trypanosomes in 8 capillaries) and by card agglutination test (CATT) 4 
Lymph node aspirate; 5 cerebrospinal fluid (CSF) examination for trypanosomes (tryps.) and 
white blood cells (cells). 
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Abstract 
 
The occurrence of blood-borne diseases and the associated haematological changes were 
investigated in 50 patients admitted at a sleeping sickness (SS) hospital in southern Sudan. 
The majority of the sleeping sickness patients had co-infection with loiasis (36%), malaria 
(30%) or both malaria/Loaisis (10%). Only 24% of the patients had a mono-infection. 
Anaemia was observed in the majority (79%) of the patients. The mean white blood cell count 
(WBC) in the patients was 10,652/µl (range: 2,760-51,320/µl). Only a minority (22%) of the 
patients showed leucocytosis but the rest showed either normal (66%) or below normal counts 
(12%). Most patients showing leucocytopenia had SS infection only, while the majority of 
those showing leucocytosis were co-infected with malaria. On the other hand most patients 
with normal WBC counts had loasis co-infection. Differential white cell counts conducted in 
23 patients revealed that most of them had lymphocytosis (83%) and eosinophilia (96%) and 
neutropaenia (61%). This study has shown that co-infections of malaria and loaisis are 
common in sleeping sickness patients in southern Sudan. The resulting haematological 
changes are severe. Apart from the SS and malaria control it might be necessary to also 
introduce control programs against nematode infections and particularly loasis in this region. 
This combined control of the three diseases would decrease morbidity and co-morbidity due 
to multiple parasitic diseases.  
 
Key words: Multiple infections, haematology, sleeping sickness, malaria, loiasis, south 
Sudan  
 
Introduction 
 
Sleeping sickness (SS), malaria and loiasis are common in Africa (WHO, 1996). The 
prevalence of sleeping sickness is estimated at 300,000 to 500,000 with an annual mortality of 
approximately 50,000 (WH0 2004). Sleeping sickness is caused by either Trypanosoma 
brucei rhodesiense, which is prevalent in eastern Africa, or T. b. gambiense, in west and 
central Africa. On the other hand, malaria is responsible for 1-3 million deaths and 300 
million infections each year, concerning mainly children under the age of five years (Breman 
2001). The vast majority of malaria infections are caused by Plasmodium falciparum, 
although P. vivax, P. ovale, and P. malariae are also prevalent. Lastly, Loasis, which is 
caused by Loa Loa, is endemic in forest and swamp areas of west and central Africa where it 
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inflicts 3 million individuals (Fain 1981). Prevalences of up to 35% have been reported in 
some of the countries (Boussinesq & Gardon 1997). An important common feature of the 
above mentioned diseases is that they are prevalent particularly among the poorer segments of 
rural communities. And since the climate in these regions is ideal for a variety of vectors, it 
therefore follows that mixed infections are inevitable in Africa. In addition, the different 
parasites reside in the same body compartments leading to similar clinical signs including 
high fever, weakness, headache, joint pains and neurological disorders.  
 
However, most studies have examined these infections as separate entities. Rather less 
attention has been paid to multiple infections (Cox 2001). During a study which was aiming at 
isolating T. b. gambiense from patients in southern Sudan we noticed a high rate of co-
infection with malaria and loaisis both detectable in blood. Here we present the 
haematological profiles and differential cell counts in these patients. 
Materials and methods 
Study area and patients 
 
A cross-sectional study was conducted on 50 sleeping sickness patients admitted at the Ibba 
hospital, which is located in Maridi County, western Equatorial province of southern Sudan 
between March and April 2003. The area comprises of an equatorial rainforest, with thick 
vegetation and a humid climate, providing a good habitat for the breeding of vectors of many 
tropical diseases. The study focused on SS patients admitted at the hospital. The patients (or 
their parents or guardians in case of children) were asked to give written consent. 
 
A questionnaire including questions on age, sex and self-reported symptoms of the disease 
was used. Other diagnosis on stool samples for detection of intestinal helminths and protozoa, 
as well as urine samples for detection of Trichomonas was undertaken for symptomatic 
patients. These results are not subject of the present analysis. 
Sample collection  
 
A sample of 2-3 ml of venous blood from each patient was collected into heparinised 
vacutainer tubes. Finger prick blood and cerebrospinal fluid (CSF) (lumbar puncture) was 
also collected. 
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Parasitological assessment 
a) Sleeping sickness 
Briefly, diagnosis of SS was done by microscropic examination of venous blood using the 
haematocrit centrifugation technique and the card agglutination test for trypanosomiasis 
(CATT) (Magnus et al. 1978). Lymph node aspirates and CSF were also examined for the 
presence of trypanosomes, and the number of white cells in the CSF was determined using a 
Neubauer haemocytometer. Patients without trypanosomes and less than 5 cells/mm3 in CSF 
were classified as 1st stage while those with trypanosomes and/or more than 5 cells/mm3 were 
classified as 2nd stage. 
 
b) Malaria and Loa loa  
Thick and thin blood smears were prepared from all patients and examined under the 
microscope for malaria and Loa loa parasites (Chadee et al. 2003). The presence of Loa loa 
was further determined using haematocrit centrifugation technique for better detection of 
microfilaria in the buffy coat. 
 
c) Haematology 
The packed cell volume (PCV), haemoglobin (HB) concentration and total white blood cell 
(WBC) counts were determined from venous blood. Haemoglobin concentration was 
determined using a haemoglobinometer while the total WBC was determined by the manual 
counting method in a haemocytometer (Cheesbrough, 2001). Twenty-three of the 50 patients 
were randomly selected and blood smears prepared for differential white cell counts. 
 
Since the mean haematological values of the local population in south Sudan have not been 
established, the normal haematological values were based on reference ranges as detailed by 
(Dacie 2001). 
 
Statistical analyses  
Data was entered in Microsoft Excel and transferred into Epi dats 2.1. Analysis was done by 
use of the statical software package STATA (version 7.0, stata). Chi Square analysis was used 
to determine difference between anaemia occurrence in female and males. 
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Results 
Patient description 
Fifty patients infected (positive by any of the techniques used) with SS patients (23 males and 
27 females) were included in the study. The mean age of the patients was 24 (0.25 – 62) 
years. The patients’ numbers of white cells in the CSF ranged from 5 to1541 cells/µl. 
However, only eight of these second stage patients had trypanosomes in CSF. The patients 
reported various disease symptoms including headache (48/50), pruritus (41/50) and 
arthragia/ myalgia (47/50), insomnia (13/50) and mental disturbance (10/50). The number of 
symptoms reported varied and an average of 3.2 symptoms was reported per patient. 
 
The majority of the sleeping sickness patients had a co-infection with either loiasis (36%), 
malaria (30%) or both malaria and loaisis (10%) (Table 1). Only 24% of the patients had a 
mono-infection of SS. Co-infection was more common in female (85%) than in the male 
patients (65%). Other cases of parastic infections noted were onchocerciasis (2) giardiasis (2), 
trichomonas (2), helminthosis (2) and amoebiasis (2).  
 
Erythrocytes 
 
The erythrocyte changes were assessed in 49 patients (data for one patient was inadvertently 
lost) and both methods of determination of anaemia-PCV and haemoglobin concentration 
gave similar findings (P>0.05-T-test). Anaemia was observed in most (80%) of the patients 
(6/11, 18/20 and 15/18 of the children, adult female, and adult male respectively) (Table 2). 
Anaemia was more common in female than in male patients (Chi Square (X2)=8.09, degree of 
freedom (df)=1 P=0.004).  
 
Leucocytes 
 
The leucocyte count (WBC) varied between the patients and a mean of 10, 652 cells/µl (range 
2,760-51,320/µl) WBC was noted. Based on the total WBC counts, the patients were 
categorized into three groups; below normal, normal, and above normal counts. The normal 
values have been previously defined by Dacie ( 2001) and vary with age and sex of an 
individual. Only a minority (22%) of the patients showed leucocytosis. However, the rest of 
the patients showed either normal (72%) or below normal counts (12%). Further analysis 
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within the three categories of WBC counts indicated that most patients (66%) showing 
leucocytopenia had SS infection only while majority (55%) of those showing leucocytosis 
were co-infected with malaria. On the other hand 52% with normal counts had loasis co-
infection (Table 3). 
 
The effect of the infections on differential white cell counts were undertaken with 23 selected 
patients. Most patients had high lymphocyte (19/23) and eosinophil (22/23) counts, while 
neutropaenia was observed in 14/23 patients (Table 4). Monocytosis was observed mainly in 
patients with SS only and all patients with SS/loasis co-infection had distinct eosinophilia. 
 
Discussion  
 
The present study demonstrated the occurrence of mixed blood-borne infections in patients 
from a hospital in southern Sudan. The majority (76%) of the SS patients had co-infections of 
malaria or Loasis. There are a few mentions of co-infections of sleeping sickness and malaria 
(Schmid et al. 2004;Wellde et al. 1989b;Wellde et al. 1989a)  and Loasis (Enyaru et al., 
2002). A few studies also report on co-infection of malaria and filariasis (Chadee et al. 2003) 
or other helminthes (Egwunyenga et al. 2001;Raso et al. 2004). 
 
Underlying reasons for the occurrence of multiple blood borne infections may be the 
favourable humid climate of southern Sudan that offers an environment that is conducive to a 
variety of vectors, including mosquitoes (Anopheles spp), tsetse flies (Glossina spp.) and deer 
flies (Chrysops spp.), which transmit plasmodium, trypanosomes, and Loa loa, respectively. 
In addition, the high prevalence of the diseases has been compounded by the longstanding 
(over 20 years) civil war in the area, which disrupted disease control programmes leading to a 
resurgence of the diseases (MSF 2001). In the present study, female patients had more often 
multiple infections than males. This may be attributed to occupational activities by females, 
such as drawing of water and collection of firewood that expose them to more contact with 
the vectors (Moore et al. 1999). 
 
Anaemia was observed in most of the patients but only two patients had severe anaemia. 
Indeed, it is known that in highly endemic malaria and SS areas, such as southern Sudan, it is 
almost inevitable that the infections will be associated with anaemia (Beales 
1997;Egwunyenga et al. 2001). For both malaria and SS, the pathogenesis of anaemia is 
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complex and multifactorial, and mainly results from a combination of increased destruction 
and reduced production of red blood cells (Abdalla 1990;Emeribe & Anosa 1991). As 
reported in other studies, the anaemia was more common in females than in males. This could 
be compounded by the fact that females had more co-infections, and biologically, they have 
lower erythrocytic values than males (Egwunyenga et al. 2001). Red blood cell dynamics 
could also be affected by a patients’ nutritional status, and by other infections which were not 
the subject of our study.  
 
The immune responses during an infection determine host resistance to the invading pathogen 
and ideally, elevated WBC levels are a good prognostic sign. In this study leucocytosis was 
observed in only a few of the patients and was mostly noted in patients with malaria co-
infection. Indeed, other studies have shown that leucocytosis is a common feature in malaria 
patients (Richards et al. 1998). However, most patients, especially those with co-infection of 
loaisis, showed an inadequate immune respons since they had either normal WBC counts or 
leucocytopaenia. Other investigations (Anosa & Kaneko 1983;Emeribe & Anosa 1991) have 
reported leucocytopaenia in late stage of SS. In addition to the leucocytopenia, most patients 
showed lymphocytosis. The latter is the main white cell reaction in trypanosomosis and 
malaria infections (Emeribe & Anosa 1991;Stephens 1986) and is geared towards elimination 
of the parasites. However, leucocytopenia indicates a depressed or exhausted immune system 
and, in this study, was mainly due to neutropenia. This feature is common in both malaria 
(Abdalla 1988) and chronic livestock trypanosomosis (Naylor 1971;Valli et al. 1979). 
Neutrophils play very significant role in parasite clearance and neutropenia could lead to 
increased susceptibility to other infections (Greenwood et al. 1973). 
 
Malaria and trypanosomiais lead to parasite-induced immunodepression. Since T. b. 
gambiense causes a chronic disease and leads to long-term immunodepression, a 
superimposed malaria infection may not only take advantage of the environment but also lead 
to enhancement of trypanosome parasitemia. In fact, concerted immuno-depression from the 
two parasites has been implicated in dramatic enhancement of parasitaemia in malaria and 
trypanosomiasis co-infections. However, the outcome of multiple interactions is not 
necessarily predictable and can be influenced by factors such as stage of infection, age, and 
sex of the host (Cox 2001). 
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The situation here is further complicated by co-infection with loa loa. In helminth (loa loa) 
infections the immune response is Th2 driven, but Th1 in protozoan infections (malaria or 
trypanosomiasis). The interaction between trypanosome and helminths is that the strong Th1 
response known to occur in trypanosomiasis infection abrogates the Th2 responses, which are 
necessary for immunity to helminths. Indeed a T. brucei and T. congolense infections in 
animals were able to counter the Th2 response leading to increased establishment and 
fecundity of nematode worms (Chiejina et al. 2003). Experimental studies have also shown 
agonistic and antagonistic interactions in trypanosome-heminthes co-infections that appeared 
to depend on which of the parasites was inoculated first (Fakae et al. 1994;Griffin et al. 
1981).  
 
There are two points worth further discussion. The interaction of the parasites in multiple 
infections further complicates diagnosis and treatment. First loa loa noted in most patients 
hinders microscopic observation of trypanosomes in the buffy coat junction (Enyaru et al., 
2002). Secondly, the occurrence of multiple infections raises an important issue relating to the 
early diagnosis and treatment of the gambiense form of SS, as its symptoms do not appear 
rapidly when compared to malaria. However in both diseases, the clinical signs in the early 
stage (high fever, weakness and headache, joint pains) and late stage (neurological disease) 
are to an extent similar. It is possible that an early trypanosome detection could be achieved 
when the patients present themselves at the hospital with malaria symptoms. Lastly, the order 
of treatment in a patient with multiple infections is critical. Like in other SS treatment centres, 
malaria was treated, followed by SS.  Onchocerciasis was treated after a patient was cured of  
SS, mainly because antifilarial chemotherapy has in some cases resulted in severe adverse 
side effects, including encephalopathy (Blum et al. 2001;Gardon et al. 1997) and could 
complicate the management of the neurological form of SS. Loasis was not treated and it is 
necessary to develop methods for its control. 
 
To summarise, this study has pointed to a high incidence of mixed malaria, SS and loasis 
infections in southern Sudan, with complex and severe haematological changes in the 
patients. Detailed studies are required in order to clearly understand the host-parasite 
interactions during such co-infections. 
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Table 1: Sleeping sickness, malaria and loiasis cases among different age groups and sexes 
admitted in Ibba hospital in southern Sudan 
 
 
 
 
 Anaemia status  Haematological parameters 
  number Mean PCV (range) Mean HB (range) 
Males      
Anaemic  15 30.0 (21-37) 10.1 (7-12.2)    >12 years 
Normal  3 41 (38-45) 13.3 (13-14) 
Anaemic 1 28 n.d.    <12 years 
Normal 3 38.3(37-40) 12.3(12.2-12.6) 
Females     
Anaemic 18 29.6 (20-34) 9.9 (7-13)    >12 years 
Normal 2 39 (36-42) 13 (12-14) 
Anaemic 5 29.4 (24-32) 9.7 (8.6-10)    <12 years 
Normal 2 42 (40-44) 14 (13-15) 
 
Table 2: Erythrocyte changes in patients among different age groups and sexes attending Ibba 
Hospital, southern Sudan 
 
 Gender Age(years 
 Male Female 0 -9 10-19 20-39 >40 
Mono-infection (n=12) 
 
8 4 3 1 7 1 
Malaria co-infection (n=15) 5 10 1 7 6 1 
Loiasis co-infection (n=18) 7 11 2 2 11 3 
Malaria and loiasis poly infection (n=5) 3 2 0 2 2 1 
Total (n=50) 23 27 6 12 26 6 
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Infection status Category of WBC counts  
SS only 
(n=12) 
SS & malaria 
(n=15) 
SS & loa loa 
(n=18) 
SS, malaria & Loa loa  
(n=5) 
Below normal (n=6) 66 16.5 16.5 0 
Normal (n=33) 18 21 52 9 
Above normal (n=11) 18 55 10 18 
 
Table 3: Leucocyte levels in patients having the various infection combinations 
 
 
 
 
Infection 
Status 
Category Lymph. Neutroph. Eosinoph. Monocyt. Basophil. 
Normal 12.5 37.5 12.5 12.5 50 
Low 12.5 67.5 0 0 12.5 
High 75 0 87.5 87.5 37.5 
SS alone 
(n=8) 
MCC 5182 2222 2741 351 190 
Normal 0 25 12.5 62.5 87.5 
Low 0 62.5 0 0 0 
High 100 12.5 87.5 37.5 12.5 
SS + 
malaria  
(n=8) 
MCC 7443 2380 1976 577 229 
Normal 20 25 0 100 100 
Low 20 75 0 0 0 
High 60 0 100 0 0 
SS + 
Loiasis 
(n=7) 
MCC 2525 1900 1564 235 20 
 MCC = mean cell counts (/µl), SS = sleeping sickness 
Table 4: Percentage of patients with different levels of leucocytes  
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Abstract 
This study aimed at isolating Trypanosoma brucei gambiense from human African 
trypanosomiasis (HAT) patients under field conditions. It was carried out in South Sudan in 
collaboration with Médecins sans Frontières-France (MSF-F). Fifty-three HAT patients 
identified during active screening surveys were recruited, most of whom were in 2nd stage 
disease (51/52). Blood and cerebrospinal fluid samples collected from the patients were 
cryopreserved using Triladyl® as cryomedium. The samples were stored at -150°C in liquid 
nitrogen vapour in a dry shipper. 18 patient stabilates could be propagated in laboratory 
rodents (immunosuppressed Mastomys natalensis and SCID mice), but only 5 of them caused 
a patent parasitaemia in Swiss white mice. Parasitaemia was highest in SCID mice. In vivo 
viability appeared to be dependent on the parasitaemia in the patient. Further subpassages in 
M. natalensis increased the virulence of the trypanosomes and all 18 isolates recovered from 
M. natalensis or SCID mice became infective to other immunosuppressed mouse models. A 
comparison of Swiss white mice, M. natalensis, C57/bl and Balb/C, all immunosuppressed, 
demonstrated that all rodent breeds were susceptible after the 2nd subpassage and developed a 
parasitaemia higher than 106/ml by day 5 post-infection. The highest parasitaemias were 
achieved in C57/bl and Balb/C. This indicated that propagation of T. b. gambiense isolates 
after initial isolation in immunosuppressed M. natalensis or SCID mice could be done in a 
range of immunosuppressed rodents.  
 
Key words: Trypanosoma brucei gambiense, propagation, cryopreservation, isolation, 
Mastomys natalensis, SCID mice, Sudan, Sleeping sickness 
 
Introduction 
 
Sleeping sickness or human African trypanosomiasis (HAT) is endemic in 36 countries in 
sub-Saharan Africa. It is estimated that 60 million people are at risk of infection, 500,000 
people are already infected and approximately 50,000 die every year (WHO Report, 2004). 
The disease is caused by Trypanosoma brucei rhodesiense and T. b. gambiense. The former 
causes an acute disease and is mainly found in east Africa, while T. b. gambiense generally 
causes a chronic disease in western and central Africa. In Sudan, HAT due to T. b. gambiense 
is highly endemic with an estimated 1 to 2 million people at risk of infection, and thousands 
of people infected.  
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Control of the disease relies mainly on chemotherapy and, to a limited extent, on vector 
control. The drugs used in Sudan are pentamidine for 1st stage and melarsoprol and 
eflornithine for 2nd stage disease. Melarsoprol, an arsenical drug, is normally the first line 
drug for treatment of 2nd stage disease. In recent years, high rates of melarsoprol treatment 
failure (>20%) have been reported in T. b. gambiense endemic areas in Uganda, Angola and 
Sudan (Legros et al., 1999; Burri and Keiser, 2001).  
 
In one area of South Sudan, Maridi county (Western Equatoria), the rate of melarsoprol 
treatment failure was found to be high (Moore and Richer, 2001). Additionally, a high fatality 
rate following melarsoprol treatment was noted (MSF Report, 2002). This has led to a change 
of treatment policy, and since September 2001 eflornithine became the first-line drug for 2nd 
stage disease in the Ibba hospital (MSF Report, 2002).  
 
The role of resistant trypanosomes in treatment failures is not well understood mainly because 
of a lack of T. b. gambiense isolates from various endemic countries. One reason for this is 
the difficulty to isolate this trypanosome species and to propagate it in laboratory rodents 
(Brun et al., 2001). The purpose of this study was to isolate T. b. gambiense from patients in 
Ibba sleeping sickness hospital. At the same time, the study investigated ways of improving 
the field isolation of T. b. gambiense in endemic areas which are hard to access. Specifically, 
we evaluated a new cryomedium (Maina et al., submitted) and later studied the propagation of 
the isolated parasites in various mouse breeds. 
 
Materials and Methods 
Isolation of trypanosomes from patients 
 
Cryopreservation medium 
Triladyl (MiniTüB GmbH & CO. KG; Tiefenbach, Germany), a medium for bull semen 
cryopreservation, was used for the cryopreservation of the blood and CSF samples from HAT 
patients (Maina et al., in press). Triladyl contains 8% glycerol, 20% egg yolk, Tris buffer, 
citric acid, fructose, and antibiotics (tylosin 5mg/l, gentamicin 25mg/l, spectinomycin 30mg/l, 
and lincomycin 15mg/l). It was stored at 4oC or at -20°C. 
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Liquid nitrogen 
Three nitrogen tanks (Taylor-Wharton) were used: one tank type 34HC (capacity 34 litres) 
and two dry shippers, CX100 (capacity 4 litres). The storage tank was kept in the MSF-F 
laboratory at Maridi and was used to refill the dry shippers. The dry shippers were taken to 
the hospitals for specimen collection.  
 
Patients 
Active screening of HAT patients was done by MSF-F in Mundri and Maridi counties, 
Western Equatoria, South Sudan (Figure 1). Identified 1st stage patients were transferred to 
Kotobi, Mundri county, and 2nd stage patients to Ibba, Maridi county. In the hospital, the 
patients were informed of the objectives and protocols of the study. To be included in this 
study the patients (or their guardians) had to give their consent (written/ thumb print).  
Only patients with confirmed T. b. gambiense infection were enrolled. Diagnosis was either 
done serologically (Magnus et al., 1978) or parasitologically (trypanosomes detected either in 
lymph node aspirate, venous blood or cerebrospinal fluid (CSF)). In the CSF the number of 
lymphocytes was determined. Patients with no trypanosomes and less than 5 cells/mm3 in 
CSF were classified as 1st stage. Those with trypanosomes and/or more than 5 cells/mm3 in 
CSF were classified as 2nd stage. Patients who had been previously treated for HAT less than 
12 months ago were considered relapses or treatment failures. 
The World Health Organization (WHO) and the Ministry of Health of Sudan People’s 
Liberation Army (SPLA) approved the study protocol. 
 
Cryopreservation of patient stabilates 
Samples of 2-3 ml of venous blood from patients were collected into heparinised vacutainer 
tubes. Samples of 2 ml of CSF were also collected from two self-reporting patients attending 
the hospital. Trypanosomes in the samples were concentrated by centrifugation at 10,000 
RPM for 10 minutes and the pellet re-suspended in Triladyl® at a 1:1 ratio for blood and 1:10 
for CSF. Aliquots of 500µl were then transferred into NUNC® ampoules. Four to five 
stabilates were prepared per patient and stored in a liquid nitrogen dry shipper in the vapour 
phase at -150°C. The dry shippers containing the stabilates were transported to the 
Trypanosomiasis Research Centre (TRC) in Kenya within a month.  
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Propagation of T. b. gambiense in laboratory rodents 
 
Laboratory animals 
Mastomys natalensis and Swiss white mice were bred at TRC. C57/bl and Balb/C mice were 
purchased from the International Livestock Research Institute (ILRI) and the Kenya Medical 
Research Institute (KEMRI), both in Nairobi, Kenya. Severe combined immunodeficient 
(SCID) (C.B-17/Icr-scid/scid), C3H (strain code 025), and FVB (strain code 207) mice were 
purchased from the Charles River Laboratories, Inc., Germany. NMRI mice were purchased 
from RCC Ltd., Itingen, Switzerland. The animals were housed under conventional 
conditions, and fed on commercial pellets and water ad libitum.  
All animals (except for SCID mice) were immunosuppressed by administration of 
cyclophosphamide at 300mg/kg body weight intraperitoneally prior to infection and re-treated 
every 10 days with 200mg/kg.  
 
Propagation of stabilates from HAT patients in M. natalensis and SCID mice 
The presence and viability of trypanosomes in the patient’s stabilate was determined by 
inoculating the stabilates in to one SCID mouse and two immunosuppressed M. natalensis. 
The stabilates were thawed rapidly in a water bath at 37oC and immediately injected 
intraperitoneally (ip) into the laboratory rodents (one stabilate into three rodents). 
Parasitaemia was monitored every other day for 60 days by examination of tail blood using 
the haematocrit centrifugation technique (HCT) and/or by the method of Herbert and 
Lumsden (1976). Parasitaemic animals were euthanised using CO2, and blood was collected 
by cardiac puncture. The infected blood (passage 1) was cryopreserved in Triladyl and 
frozen in the vapour phase of a liquid nitrogen container at -2oC/minute and finally stored in 
liquid nitrogen. Successful stabilates were given an isolation code different from the original 
patient stabilate. 
Rodents that remained aparasitemic for 60 days after inoculation of cryopreserved material 
were euthanised and blood collected by cardiac puncture. For each rodent, eight capillaries 
were prepared and examined for trypanosomes using the HCT method. If no patent infection 
could be found, another two M. natalensis were injected with another stabilate. 
 
Propagation of stabilates from HAT patients in Swiss white mice 
The eighteen stabilates which could be propagated either in immunosuppressed M. natalensis 
or in SCID mice were used to evaluate the susceptibility of Swiss white mice for T. b. 
Isolation and propagation of T.b. gambiense from patients 
___________________________________________________________________________ 
 73 
gambiense after immunosuppression. An original stabilate from the patients was thawed and 
aliquots injected in to one Swiss white mouse and one M. natalensis, both immunosuppressed. 
 
Genotypic characterization 
Trypanosomes (passage 1) were purified using an anion exchange column (Lanham and 
Godfrey, 1970) and  DNA was extracted using the Puregene DNA extraction kit (Gentra 
Systems, Minneapolis, USA) as previously described by Matovu et al. (2001b).  
 
Amplification of the serum resistance-associated (SRA) gene and the T. b. gambiense specific 
glycoprotein (TgsGP) was done as previously described by Radwanska et al. (2002a and b). 
However, for both genes a nested PCR was done. For SRA, the two sets of primers used were 
SRA-out-s (5-CCTGATAAAACAAGTATCGGCAGCAA-3’) and SRA-out-as (5’-
CGGTGACCAATTCATCTGCTGCTGTT-3’) and SRA-inner-s (5’-ATA GTG ACA TGC 
GTA CTC AAC GC-3’), SRA-inner-as (5’-AAT GTG TTC GAG TAC TTC GGT CAC 
GCT-3’). For the T. b. gambiense specific glycoprotein (TgsGP) gene the primer pairs were: 
TbsGP-outer-s (5’-GCGTATGCGATACCGCAGTAA-3’) and TbsGP-outer-as (5’-
GCTTCAACCGCCGCTGCTTCTA-3’); TbsGP-s (5’-GCTGCTGTGTTCGGAGAGC-3’) 
and TbsGP-as (5’-GCCATCGTGCTTGCCGCTC-3’).  
 
For control PCRs, the actin gene was amplified using primers act-s (5’-
CCGAGTCACACAACGT-3’) and act-as (5’-CCACCTGCATAACATTG-3’). The 
amplifications were done in 50µl reaction containing PCR buffer (Qiagen), 200mM of the 
four dNTPs, 1uM of each primer, and Taq polymerase in a PTC 200 Peltier (MJ Research) 
thermocycler under the following conditions: initial denaturation at 94°C for 3 minutes; 30 
cycles of 94°C for 45 seconds, 62°C (55°C for actin) for 45 sec and 72°C for 120 sec; a final 
extension for 10 min, followed by rapid cooling at 4°C. 8µl of the PCR product were 
analyzed by electrophoresis in a 1.25% agarose gel. The gels were stained with ethidium 
bromide (0.2µg/ml) and visualized under UV. 
 
For sequencing, two independent PCR reactions were pooled, purified using QIAquick 
columns (Qiagen, Basel, Switzerland), and sequenced with the Big Dye Terminator kit 
(Applied Biosystems). The products were run at the Computational and Molecular Population 
Genetic Lab (CMGP, Zoology Department, University of Bern) on the ABI-sequencer. 
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Susceptibility of various strains of mice to T. b. gambiense isolates 
The susceptibility of various strains of mice to the T. b. gambiense isolates was determined in 
two independent experiments. In one test, the susceptibility of immunosupressed Swiss white 
mice to the 18 isolates (passage 1) was determined. Each isolate was tested in two mice and at 
an inoculum of 4x105 trypanosomes.  
 
In the second experiment, the growth pattern of five randomly selected isolates was 
determined in C57/bl, Balb/C, Swiss white, NMRI, C3H, FVB and M. natalensis. Prior, the 
parasites (from the primary propagation) were passaged twice in M. natalensis and then in the 
respective rodent strain. Trypanosomes were harvested from a donor rodent and inoculated 
into four rodents. Each animal was inoculated with 4x105 trypanosomes. Thawing of 
stabilates, inoculation, and parasitaemia determination were carried out as described earlier.  
 
Results 
Patients 
Fifty-three confirmed HAT patients were enrolled in the study. 49 were from Mundri, two 
from Maridi, one from Yambio, and one from Juba county. The mean age of the patients was 
24 years (range 0.25- 62) with >90% being below 40 years. Most patients (51/53) were in the 
2nd stage of the disease, with CSF lymphocyte numbers ranging from 5 to 1541/mm3. Seven 
of the patients had previously been treated (7-12 months before): four with eflornithine (at 
400mg/kg/day for fourteen days) and three with pentamidine (4mg/kg/day for seven days).  
Blood samples were collected from 50 out of 52 patients: 42 patients were parasite positive in 
the blood and eight were aparasitaemic. Samples of CSF were collected from two patients 
attending the hospital for passive screening. For all other patients a lumbar puncture had 
already been done in the field during active screening, and for ethical reasons a second lumbar 
puncture was not performed in the hospital. 
 
Primary propagation of stabilates from patients  
Details of the patients of whom trypanosomes could be isolated are shown in Table 1. Fifty 
blood and two CSF samples were inoculated into both M. natalensis and SCID mice. Of the 
blood samples, 16 caused patent infections in either rodent species while the two CSF 
samples did not lead to a parasitaemia in the rodents. For the 34 patients of whom the blood 
stabilates could not be propagated in the first attempt, a second stabilate was inoculated in two 
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immunosuppressed Mastomys natalensis. However, only two more isolates (K03030 and 
K03032) could be obtained in this second propagation attempt. A slightly higher recovery was 
obtained in M. natalensis (14/18) as compared to SCID mice (12/18). Only 8/18 stabilates 
could be propagated in both rodents. The stabilates had a similar pre-patent period in SCID 
mice (10.25 ± 4.26 days) and in M. natalensis (11.25 ± 6.3 days). In M. natalensis however, 
only 3/14 stabilates had parasitaemias of 106/ml or higher, whereas in the SCID mice 9/12 
stabilates reached that parasitaemia. Patient stabilates that were successfully inoculated in 
rodents were designated with the name ‘Mundri’ (the name of the county in South Sudan 
where all the patients came from) and a consecutive number; furthermore they are termed 
isolates. The details of the viable isolates are shown in Table 2. 
 
Determination of the suitability of Swiss white mice for patient stabilates 
Only five (I03030, I03037, K03048, K03045, and K03051) of the eighteen patient stabilates 
which could be propagated in either immunosuppressed M. natalensis and/ or in SCID mice 
caused patent infection in immunosuppressed Swiss white mice (Table 3). Parasitaemias in 
Swiss white mice were low (apart from K03048) and could only be detected by the HCT 
method. With one stabilate (K03051) parasitaemia was sporadic and inconsistent. The 
parasitaemia was generally much higher in M. natalensis and SCID mice than in Swiss white 
mice. 
 
 Genotypic characterization 
T. brucei subspecies-specific genotyping was performed by PCR using the serum resistance-
asscoiated gene SRA as a marker for T. b. rhodesiense (Radwanska et al., 2002a) and the T. b. 
gambiense-specific glycoprotein gene TbgGP for T. b. gambiense (Berberof et al., 2001). The 
marker genes were amplified from genomic DNA by nested PCR and analyzed on agarose 
gels (Fig. 2). All isolates tested were positive for TbgGP and negative for SRA. To verify that 
the correct gene was amplified, PCR products were directly sequenced. Apart from a few 
silent mutations the obtained sequence (GenBank accession DQ224158) was identical to that 
published for TgsGP (GenBank accession AJ277951), proving that the isolated trypanosomes 
were indeed T. b. gambiense. 
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Susceptibility of mice to secondary propagation of T. b. gambiense 
All the 18 isolates (Mundri 1 to 18, first passage) inoculated into immunosuppressed Swiss 
white mice caused patent infection, with a pre-patent period of 4 days. Most of the isolates 
(11/18) caused low and inconsistent parasitaemia (less than 104/ml), but the remaining 
isolates (Mundri 02, 03, 04, 06, 08, 14, and 17) grew to high parasitaemia with levels over 106 
trypanosomes/ml (data not shown). 
 
The growth patterns of five randomly selected isolates (passage 4) were compared in 
immunosuppressed C57/bl, Balb/C, Swiss white and M. natalensis (Table 4). The parasites 
were infective for all rodents used, with a similar prepatent period (3 days) and a parasitaemia 
higher than 106 trypanosomes/ml by the 5th day. There was variation in the growth pattern 
between the isolates and between rodent strains. For all five isolates, the highest parasitaemia 
(over 5 x 107 trypanosomes/ml) was noted in C57/bl mice. Overall, C57/bl and Balb/C 
sustained higher parasitaemias (over 106/ml) for several days than Swiss white or M. 
natalensis. In all isolates the parasitaemias dropped to undetectable levels by day 16 post 
infection, and only a few deaths (4/80) were noted during the 60 day observation period. In 
NMRI, C3H and FVB mice parasitaemia was always very low and far below the parasitaemia 
in C57/bl and Balb/C (data not shown). 
 
Discussion 
This is the first report of successful isolation of T. b. gambiense from patients in South Sudan. 
18 viable isolates could be cryopreserved under field conditions using the new cryomedium 
Triladyl (Maina et al., in press). In previous studies, low recovery rate or complete loss of T. 
b. gambiense populations following cryopreservation in medium containing 10% glycerol 
have been reported (Brun et al., 2001; Matovu et al., 2001a). The achieved recovery rate of 
43% is very satisfactory and may be attributed to the superior cryopreservation medium 
Triladyl.  
 
Viability of the isolates in rodents also depended on the degree of parasitaemia in the patients. 
Twenty-nine (about 78%) of the 37 tested patients had trypanosomes in the blood but 
parasitaemia was low (only detectable by HCT) and varied between the patients. There was a 
direct correlation between parasitaemia in the patient and viability in rodents, i.e. the recovery 
rate was higher in the category isolated from patients with detectable parasitaemia as 
compared to patients with undetectable parasitaemia. Earlier reports also noted that the 
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limited infectivity of T. b. gambiense for laboratory rodents led to low isolation success 
(Dukes et al., 1989; Aerts et al., 1992), especially from patients with low parasitaemia.  
 
In the current study we used the African rodent M. natalensis (immunosuppressed) for 
primary propagation of the patient stabilates on a comparative basis to SCID mice which have 
no functional T and B lymphocytes (Bosma et al., 1983). M. natalensis was reported to be a 
better model for T. b. gambiense than rats and mice (Mehlitz, 1978) and have been 
extensively used for propagation studies (Gibson et al., 1978; Zillmann and Mehlitz, 1979; 
Dukes et al. 1989; Aerts et al., 1992; Matovu et al., 2001a). Inoue et al (1998) first described 
the good susceptibility of SCID mice for T. b. gambiense isolates. The parasitaemias attained 
were higher in SCID mice than in immunosuppressed M. natalensis. That finding could be 
confirmed by our study. The use of SCID mice is however restricted by the high costs of the 
mice. On the other hand, breeding colonies of M. natalensis were successfully established at 
institutes in East Africa. 
 
Normal in- or outbred laboratory mice have generally not been found to be susceptible for T. 
b. gambiense isolates, though they can easily be infected with T. b. rhodesiense isolates. 
However we found that after immunosuppression, different breeds of normal laboratory mice 
could be infected with the 2nd or 3rd passage of our Mundri T. b. gambiense isolates. Even 
stabilates prepared from patients were infective for immunosuppressed Swiss white mice, 
though with a lower success rate (5/18) as compared to M. natalensis (14/18) or SCID mice 
(12/18). However, after a second passage, all 18 isolates were infective for 
immunosuppressed Swiss white mice, and seven of them resulted in a parasitaemia >106/ml. 
In other mouse strains, (C57/bl, Balb/C, NMRI, C3H and FVB) the parasitaemia was very 
low, except for the three isolates K03028, K03048, K03043 which reached parasitaemias 
>105/ml in C57/bl and Balb/C by day 14 post-infection. Passaging the isolates at least three 
times increased their virulence resulting in a parasitaemia >107/ml. Earlier reports indicated 
that C57/bl mice are able to control a trypanosome infection (Hertz et al., 1998), but 
immunosuppression of C57/bl resulted in a higher parasitaemia than in untreated mice (Black 
et al., 1983). 
 
In conclusion, we recommend that infected blood samples from T. b. gambiense patients 
should be cryopreserved in Triladyl medium. Primary propagation and the subsequent 
subpassage should be done in immunosuppressed M. natalensis or in SCID mice. Further 
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subpassages can then be done in immunosuppressed laboratory mice (e.g. C57/bl or Balb/C). 
Available mouse breeds should be screened after immunosuppression with cyclophosphamide 
at 300 mg/kg prior to infection and repeated once/week at 200 mg/kg. This propagation 
scheme is efficient and also economical. It will allow the characterization of T. b. gambiense 
from various hot spots of Central Africa, hence enhancing the monitoring of drug resistant 
trypanosomes. These new T. b. gambiense isolates are a great resource for further scientific 
investigations. Their characterization, especially for drug sensitivity, will assist in elucidating 
the cause of the high melarsoprol treatment failure rates reported in the area. 
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Figure 1: Study site in Western equatorial in South Sudan. Grey squares the origin of the 
patients while black circles indicate the MSF-laboratories. 
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Figure 2: Genotypic characterization: Amplification of the T. b. gambiense-specific 
glycoprotein (TgsGP, top) and the serum resistance-associated gene (SRA, bottom) in 
trypanosomes isolated from HAT patients. As all 18 stabilates gave the same result only 6 of 
them are shown here (lanes 1-6). T. b. rhodesiense STIB 704 (lane 7) and T. b. gambiense 
STIB 754 (lane 8) were used as controls. 
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Patient 
stabilate 
Bomas  Age Sex Proof of trypanosomes in: CSFd 
 
(village) (yrs) Male:M 
Female:F Blood
a Lymphb CSFc cells/mm3 
        
(not done (n.d.); positive +; 
negative -) 
  
I04008 Midi 19 F n.d. + - 8 
I03037 Amandi 12 F n.d. + - 49 
K03028 Nyau 1 25 M ++ n.d. - 6 
K03048 Buangyi 20 M +++ n.d. - 58 
K03051 Nyau 1 23 M n.d. n.d. - 50 
K03030 Goribalan 21 F ++ n.d. - 4 
K03042 Nyau 1 20 M n.d. + - 10 
I04019 Lazoh 10 M ++ + - 17 
K03043 Wiri Lui 6 M +++ + - 9 
I04015 Singo 12 M + + - 104 
K03045 Nyau 1 12 M n.d. n.d. - 8 
I04022 Lazoh 9 F +++ + - 8 
K03010 Mundri 27 M +++ + - 61 
I04021 Gingo 23 F ++ + - 45 
I03030 Lazoh 12 F n.d. + - 8 
K03044 Nyau 1 12 F + + - 20 
K03032 Singirigwa 22 F +++ n.d. + 783 
K03054 Moto 25 M ++ n.d. - 22 
 
Table 1: T. b. gambiense isolates from Mundri County which could be propagated in 
laboratory rodents. The blood samples were cryopreserved in Triladyl® and stored in 
nitrogen vapour in dry shippers. All patients had new infections and were in 2nd stage disease, 
apart from one patient in 1st stage (stabilate K03030) and another patient (stabilate K03048) 
who had been treated 12 months earlier with eflornithine. 
aThe haematocrit centrifugation technique was used to estimate parasitaemia in the blood and 
graded as + (1-5), ++ (6-15) and +++ (more than 15 trypanosomes visible). b lymph node 
aspirate; c cerebrospinal fluid; d counted lymphocytes in the cerebrospinal fluid. 
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Isolate No. SCID mice (Passage 1)   M. natalensis (Passage 1) Patient 
stabilate 
 
Pre-
patent 
period 
Parasitaemia at 
freezing (day 
post infection) 
  No. with 
patent 
infection 
Pre-
patent 
period 
Parasitaemia at 
freezing (day 
post infection) 
I04008 Mundri 01 7 1.6 x 107 (7.2)   2/2 12 +++ (14) 
I03037 Mundri 02 7 1.6 x 107 (7)  ½ 8 +++ (10) 
K03028 Mundri 03 11 1.6 x 107 (12)  2/2 4 +++ (6) 
K03048 Mundri 04 4 1.6 x 107 (6)  2/2 4 2.5 x 104 (5) 
K03051 Mundri 05 7 0.8 x 107 (14)  ½ 23 ++ (26) 
K03030 Mundri 06 11 1 x 106 (21)  ¼ 9 ++ (11) 
K03042 Mundri 07 14 ++ (14)  2/2 10 ++ (12) 
I04019 Mundri 08 13 + (13)  2/2 21 3.2 x 107 (25) 
K03043 Mundri 09 5 3.2 x 107 (9)  0/4 - - 
I04015 Mundri 10 11 1.6 x 107 (11)  0/4 - - 
K03045 Mundri 11 17 1.0 x 106 (22)  0/4 - - 
I04022 Mundri 12 16 2.5 x 104 (24)  0/4  - 
K03010 Mundri 13 - -  2/2 3.5 0.8 x 107 (5) 
I04021 Mundri 14 - -  ½ 18 2 x 106 (21) 
I03030 Mundri 15 - -  2/2 6 2.5 x 104 (7) 
K03044 Mundri 16 - -  ½ 11 +++ (13) 
K03032 Mundri 17 - -  ¼ 17 +++ (18) 
K03054 Mundri 18 - -   ½ 11 + (13) 
 
Table 2: Infectivity of T. b .gambiense isolates from Mundri County for immunosuppressed 
Mastomys natalensis and SCID mice. Primary propagation was done in two 
immunosuppressed M. natalensis and one SCID mouse for each isolate. Parasitaemia was 
monitored starting day 3 post-infection and every other day for 60 days. When trypanosomes 
were visible by wet film, parasitaemia was estimated by the method of Herbert and Lumsden 
(1976) and graded as antilog trypanosomes/ml. At low levels of parasitaemia, the haematocrit 
centrifugation technique was used. Parasitaemia was graded as + (1-5), ++ (6-15) and +++ 
(more than 15 trypanosomes visible). 
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Patient 
stabilate 
M. natalensis   Swiss white mice 
 
Pre-
patent 
period 
Highest 
parasitaemia 
Days to peak 
parasitaemia 
 Pre-
patent 
period 
Highest 
parasitaemia 
Days to peak 
parasitaemia 
  
days antilog     days Antilog   
I03037 17 6.3 30   28 +++ 28 
K03048 5 7.8 17  3 8.4 17 
K03051 7 6.3 17  12 + 12 
K03045 21 6.3 24  5 + 5a 
I03030 - n/a n/a   33 ++ 38 
 
 
Table 3: Primary propagation of blood stabilates from patients in immunosuppressed 
Swiss white mice compared to immunosuppressed M. natalensis 
Five of the 18 stabilates which could successfully be propagated in SCID mice or 
immunosuppressed M. natalensis (Table 2) could also be propagated in immunosuppressed 
Swiss white mice. One Swiss white mouse and one Mastomys natalensis for comparison were 
inoculated with a primary stabilate from patients. Parasitaemia was monitored every other day 
for 40 days. Parasitaemia was estimated as described in Table 2. 
a
 Parasites were only detected on day five post infection, thereafter, the mouse was negative 
through to day 21 when it died 
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Mean Pre-patent 
period (in days) 
Period over 106/ml Highest 
parasitaemia  
Isolate No. 
(patient 
stabilate) 
Rodent breed 
(number of mice 
developing 
infection) 
(mean duration in 
days) 
(Days post 
infection) 
Mundri 02 C57/black 3 (3/4) 4-16 (12.5) 2.5 x108 (7) 
(I03037) Balb/C 3 (4/4) 4-14 (4.25) 1.6 x 107 (8.5) 
 
Swiss white 3 (3/4) 5-7 (2) 0.8 x 107 (6) 
 
M. natalensis 3 (3/4) 6-8 (2) 3.2 x 106 (7) 
Mundri 05 C57/black 3 (3/4) 5-9 (4.66) 5.0 x107 (7.66) 
(K03051) Balb/C - - - 
 
Swiss white 3 (4/4) 5-16 (4.5) 1.3 x107 (8.25) 
 
M. natalensis 3 (4/4) 6-7 (1.5) 4.6 x106 (6) 
Mundri 09 C57/black 3 (4/4) 5-8 (3.75) 7.4 x 107 (6.75) 
(K03043) Balb/C 3 (4/4) 5-9 (4.75) 6.4 x 107 (7.25) 
 
Swiss white 3 (4/4) 5-7 (3) 1.4 x 106 (6.5) 
 
M. natalensis 3 (3/4) 5-7 (3) 0.8 x 107 (6) 
Mundri 13 C57/black 3 (4/4) 5-14(6.25) 1.5 x 108 ( 7.5) 
(K03010) Balb/C 3 (4/4) 5-14 (6.26) 8.9 x 107 (7.5) 
 
Swiss white 3 (4/4) 5-7 (1.75) 3.2 x106 (6.25) 
 
M. natalensis 3 (2/4) 5-7 (2.5) 1.1 x107 (5) 
Mundri 17 C57/black 3 (3/4) 5-18 (13) 5.0 x 108 (14) 
(K03032) Balb/C 3 (3/4) 6-9 (3.33) 5.0 x 107 (7.33) 
 
Swiss white 3 (4/4) 6-7 (2) 5.0 x 106 (6.5) 
  
M. natalensis 3 (4/4) 5-7 (3) 6.4 x 107 (7) 
 
 
Data shown are means. Group size = 4. 
 
 Table 4: Comparison of the growth characteristics of T. b. gambiense isolates in 
different rodents. The animals were immunosuppressed with cyclophosphamide 
300mg/kg prior to infection. Each animal was inoculated with 4 x 104 trypanosomes 
(passage 3) intraperitoneally. Parasitaemia was monitored every other day by 
examination of tail blood for 20 days as described in Table 2. 
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Abstract 
 
As a consequence of drug resistance problems, melarsprol was replaced by eflorinthine as 
first line drug in many treatment centres in south Sudan. Resistance of trypanosomes to 
melarsoprol is ascribed to reduced uptake of the drug via the P2 nucleoside transporter. The 
aim of this study was to look for evidence of drug resistance in T. b. gambiense isolates from 
sleeping sickness patients in Ibba, South Sudan, an area of high melarsoprol failure rate. 
Eighteen T. b. gambiense stocks were phenotypically and genotypically characterized. In 
vitro, all isolates were sensitive to melarsoprol, melarsen oxide, and diminazene. Infected 
mice were cured with a four day treatment of 2.5 mg/kg bwt melarsoprol, confirming that the 
isolates were sensitive. The gene that codes for the P2 transporter, TbATI, was amplified by 
PCR and sequenced. The sequences were almost identical to the TbAT1sensitive reference, 
except for one point mutation, C1384T resulting in the amino acid change proline-462 to 
serine. None of the described TbAT1resistant-type mutations were detected. In a T. b. gambiense 
sleeping sickness focus where melarsoprol had to be abandoned due to the high incidence of 
treatment failures, no evidence for drug resistant trypanosomes or for TbAT1resistant-type 
alleles of the P2 transporter could be found. These findings indicate that factors other than 
drug resistance contribute to melarsoprol treatment failures. 
  
Key words: T. b. gambiense, Sudan, Melarsoprol, TbAT1 gene, Drug sensitivity 
 
Introduction 
 
Human African Trypanosomosis (HAT) caused by Trypanosoma brucei gambiense is 
widespread in western and central Africa - eastwards from Senegal to Zaire, southwestern 
Sudan and northwestern . It is estimated that 60 million people are at risk of infection, 
500,000 people are already infected and approximately 50,000 die every year (WHO 2004). 
Control of the disease depends on chemotherapy but only a small number of drugs are 
available. The choice of drug further depends on the stage of the disease. The early stage 
relies on pentamidine and the late stage, when trypanosomes have invaded the CNS, on 
melarsoprol, eflornithine and nifurtimox. 
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Melarsoprol, an arsenical, is the first-line drug for treatment of the 2nd. stage disease. 
Treatment failure rates of 3% to 9% are normal and are attributed to patient-related factors 
(concomitant infections, nutritional status etc). However, in recent years high rates of 
melarsoprol treatment failures (>20%) have been reported in T. b. gambiense endemic areas 
(Burri & Keiser 2001;Legros et al. 1999;Ruppol & Burke 1977) and there has been a growing 
interest in the cause(s). Since drug levels in blood or CSF were not found to be different 
between relapse and successfully treated patients (Burri & Keiser 2001), drug resistance has 
been suggested as a likely cause for melarsoprol treatment failures. Melarsoprol resistance has 
been induced in T. b. brucei laboratory strains and was shown to be caused by loss of the P2 
adenosine transporter that mediates also uptake of melarsoprol and diamidines (Carter and 
Fairlamb 1993, Carter et al., 1995). Subsequently it was shown that the transporter is encoded 
by the TbAT1 gene (Maser et al. 1999;Matovu et al. 2003) and recent studies indicated a 
possible link between particular TbAT1 alleles and occurrence of relapses (Maser et al. 
1999;Matovu et al. 2001b). However, all studies dealing with field isolates have focused on 
genetic markers of resistance rather than drug sensitivity testing, probably because of the 
challenges in isolation and propagation of T. b. gambiense. Thus, it has not been clarified 
whether melarsoprol treatment failures are actually caused by drug-resistant trypanosomes 
(Brun et al. 2001;Matovu et al. 2001a). 
 
We recently isolated 18 T. b. gambiense stocks from Ibba centre, Maridi county, western 
Equatorial, south Sudan where high treatment failure rates had been reported (Moore & 
Richer 2001). The trypanosome isolates were propagated and the sensitivities to melarsoprol, 
melarsen oxide, pentamidine, diminazene, DB 75 and nifurtimox determined in vitro. The 
sensitivity of nine of these isolates to melarsoprol was further tested in vivo. Then, the TbATI 
gene was amplified, sequenced and compared with published sequences of melarsprol 
sensitive and resistant isolates.  
 
Materials and methods 
Trypanosomes 
Eighteen T. b. gambiense stocks isolated in 2003 from HAT patients attending the MSF-F 
Ibba hospital in Maridi, western Equatorial, south Sudan, were used (Maina et al., submitted). 
Trypanosoma b. gambiense STIB 930 (a derivative of TH1/78E (031) which was isolated 
from a patient in Cote d’-Ivoire in 1978 was used as the reference sensitive strain. 
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In vitro drug sensitivity assay 
The medium used was a mixture of RPMI 1640 and MEM (1:1), supplemented with 5% heat-
inactivated fetal bovine serum (FBS), 12% inactivated human serum, 0.05 mM bathocuproine 
sulphonate, 0.12 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 2 mM L-glutamine and 1.5 
mM L-cysteine. Trypanosome isolates were propagated in laboratory rodents and harvested 
by cardiac puncture. Separation of the trypanosomes was as described by Lanham and 
Godfrey ( 1970). Trypanosomes (2 x 106 ml-1) were incubated in 96-well microtiter plates at 
37oC in a humidified atmosphere containing 5% CO2 with serial dilutions of the trypanocidal 
drugs (in duplicate) for 24 hours. Tritiated hypoxanthine was then added to each well giving a 
final concentration of 1 µCi/well and the plates were incubated for a further 16 hours. 
Trypanosomes were then harvested on a multimash 2000 cell harvester (Dynatech) where the 
parasites were lysed hypotonically and macromolecules trapped on filter paper. The filters 
were dried in a microwave at 85°C and radioactive incorporation measured by liquid 
scintillation counting. The number of counts per minute for trypanosomes incubated in 
different drug concentration was expressed as a percentage of control cultures. IC50 were 
calculated by linear interpolation (Huber & Koella 1993). The test was repeated at least three 
times. Data are presented as means and standard deviation (SD).  
 
In vivo drug sensitivity determination in mice 
Swiss White mice weighing 20-25 g were used. Briefly, the mice were immunosuppressed 
with 300 mg/kg bwt cyclophosphamide one day prior to infection and again on days 14 and 
28 post infection. Nine of the 18 isolates were tested. Briefly, for each stabilate, eight mice 
were infected with T. b. gambiense stocks intraperitoneally with 5 x 104 trypanosomes. One 
group of four mice was treated with 2.5 mg/kg bwt melarsoprol daily for four days (day 4-7) 
while the other group served as an untreated control. Parasitaemia was determined by 
examination of tail blood using the HCT method (Woo 1970) as follows; on day four (before 
treatment), on day seven (immediately after end of treatment), thereafter twice a week for the 
first two weeks and then once a week until day 60. Mice with no detectable parasitaemia at 
day 60 were considered cured.  
PCR 
DNA was extracted from bloodstream form (BSF) trypanosome isolates (passaged once in a 
laboratory rodent) using the Puregene DNA extraction Kit (Gentra Systems, Minneapolis, 
USA) (Matovu et al. 2001b).  
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Full length TbAT1 was amplified from genomic DNA by hot start PCR with primers ant-s (5’-
GCCCGGATCCGCTATTATTAGAACAGTTTCTGTAC-3’) and ant-as (5’-
GCCCCTCGAGCCGCATGGAGTAAGTCTGA-3’). This initial PCR step was followed by 
second round of nested PCR using the primer pair ATLF (5-
GAAAGCTTAATCAGAAGGATGCTCGGGTTTGACTACA-3) and ATLR (5-
GAGGATCCTGAACAGTATTCGTATGACGATTAGTGCTAC-3). For control PCR, the 
actin gene was amplified using primers act-s (5-CCGAGTCACACAACGT-3) and act-as (5-
CCACCTGCATAACATTG-3). The amplification was done in 50 µl reaction volume 
containing 1 x PCR buffer (Qiagen), 200 mM of each dNTP, 1 µM of each primer, and 1 unit 
of Taq polymerase in a PTC 200 Peltier (MJ Research) thermocycler under the following 
conditions: initial denaturation at 94 OC for 3 minutes; 30 cycles of 94 OC for 45 seconds, 55 
OC for 45 seconds and 72 OC for 120 seconds; a final extension at 72 OC for 10 min, followed 
by rapid cooling at 4 oC. The products were analyzed by gel electrophoresis through 1.25% 
agarose gel stained with ethidium bromide (0.2µg/ml) and visualized under UV light. 
 
Cloning of PCR products 
For two isolates (I04015 and KO3048) the TbATI gene was cloned. The PCR products were 
precipitated (10% volume of 3 M NaCl and 2.5 volumes of ethanol), re-dissolved in H2O, and 
ligated into the vector pGEM ® T-easy (Easy Vector System, Promega USA). The plasmids 
were isolated from transformed E. coli DH5α and purified using the QIAprep Spin Miniprep 
Kit. Inserts were sequenced with the standard primers T7 and SP6. 
 
Direct sequencing of PCR products 
The TbAT1 gene of ten of the isolates was sequenced. Two independent PCR reactions were 
pooled and purified (QIAquick kit, Qiagen, Basel, Switerzland). For each pool, four 
sequencing reactions were done in a PTC 200 Peltier (MJ Research) thermocycler under the 
following conditions: 40 cycles of 96OC for 50 seconds, 96OC for 10 seconds, 50OC for 10 
seconds; 60OC 4 minutes. The excess dye was removed (DyeEx™ 2.0 spin columns, Qiagen), 
sample dried and run at the CMG sequencing facility of the Zoology Department, University 
of Bern.  
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Results 
In vitro sensitivity of  isolates 
The sensitivities to melarsoprol, melarsen oxide, pentamidine, diminazene, DB 75 and 
nifurtimox of 16 T. b. gambiense isolates, were tested in vitro (for two isolates parasitaemia 
achieved was too low for the assays). Sensitivity of the isolates to melarsoprol (5 ± 1.47nM) 
and melarsen oxide (3.9 ± 0.9nM) were significantly similar. The sensitivities to diamidines; 
pentamidine, diminazene and DB 75 were within a similar range.  In addition, the sensitivities 
to all the drugs tested were similar to those of a reference sensitive isolate T. b. gambiense 
STIB 930 (Table 1). Thus none of the isolates showed reduced sensitivity to the drugs tested.    
 
In vivo drug sensitivity determination in mice 
In order to test the in vivo susceptibility of the T. b. gambiense isolates to melarsoprol, 
immunosuppressed Swiss White mice, eight per stabilate, were infected. The animals were 
parasitaemic by the fourth day post-infection. All melarsoprol treated mice were cured. 
Trypanosomes were not detectable from day seven (immediately after the end of treatment) 
and the animals remained aparasitaemic during the whole experimental period of 60 days. In 
addition, none of the treated animals died during the experimental period.  
 
The control groups remained parasitaemic with the parasitaemia pattern varying between the 
isolates. The parasitaemia was sporadic and inconsistent for most of the isolates. The T. b. 
gambiense isolates caused a chronic disease and some mice died during the experimental 
period (Table 2). 
 
Characterization of TbAT1 
As determined by PCR, the TbAT1 gene was present in all the T. b. gambiense isolates. The 
PCR products had the expected size of about 1400 bp. The PCR products of 10 of the isolates 
were directly sequenced and compared to the published reference sequences; TbAT1 sensitive 
(GenBank accession number AF152369) and TbAT1 Resistant (accession number AF1552370) 
(Maser et al. 1999)(Figure 2). The TbAT1 sequences of the 10 isolates were almost identical 
to the TbAT1 sensitive reference sequence. However, at position 1384 a new mutation was noted 
in all the isolates, C1384T. In addition, two new mutations were noted in isolate I03022, 
A83G and C1086T. The mutation C1086T is silent while A83G results in amino acid change 
asparagine-28 to serine. C1384T mutates proline-462 to serine. The amplified genes lacked 
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any of the nine mutations described from melarsoprol resistant isolates. Direct sequencing of 
pooled PCR products from independent reactions has the advantage that mutations introduced 
by Taq polymerase are not seen in the electrophoretogram. However, since the T. b. 
gambiense isolates were not cloned, direct sequencing of PCR products will not detect TbAT1 
alleles present only in a minority of the trypanosomes. We also determined the sequence of 
cloned PCR products and found three more mutations: a trinucleotide deletion of codon 26 
and two silent mutations, C-1086 to T and A-1168 to G (Table 3). 
 
Discussion  
 
The MSF-F hospital in Ibba was the only second-stage sleeping sickness (SS) treatment centre 
in western equatorial south Sudan, serving both Maridi and Mundri counties. In this hospital, 
high melarsoprol failure rates (20%) have been reported (Moore & Richer 2001). In addition, 
a high death rate following melarsoprol treatment was also being recorded (MSF 2001). The 
efficacy of melarsoprol was questioned leading to a change in the treatment approach. In 
September 2001, DFMO became the first-line drug for the 2nd stage disease. However, this 
was done without determining the cause of the melarsoprol treatment failures. In line with 
current priorities (Brun et al. 2001;WHO 1999) this study aimed at elucidating the cause(s) of 
the high rates of treatment failure in that area. 
 
Decreased sensitivity in the trypanosomes population is suspected to be an important 
contributor to treatment failure (Matovu et al. 2001a). However, sensitivity determination was 
done using only a few recently isolated parasites (Brun et al. 2001;Matovu et al. 2001a) 
mainly because T. b. gambiense is difficult to isolate and propagate (in vitro or in rodent 
hosts) (Brun et al. 2001). Here we used eighteen T. b. gambiense stocks that were recently 
isolated from HAT patients attending the Ibba SS hospital. In vitro drug sensitivity tests 
indicated that the isolates are sensitive to melarsoprol and melarsen oxide. IC50 values to 
melarsoprol were in the same range as those of older T. b. gambiense isolates from Cote 
d'Ivore (Brun et al. 2001). In vivo the isolates were sensitive to 2.5 mg/kg bwt melarsoprol 
administered for four consecutive days. 
 
The use of melarsoprol for in vitro determination of arsenical sensitivity has been questioned 
mainly because in plasma, melarsoprol is rapidly metabolized to form active metabolites 
including melarsen oxide. Melarsen oxide is the active drug not melarsoprol (Keiser et al. 
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2000). Nevertheless most laboratories continue to use melarsoprol in tests since it is readily 
available as compared to melarsen oxide. In this study therefore, we assessed the sensitivities 
of the T. b. gambiense isolates to these two compounds. There was no difference in the IC50 
values obtained with melarsoprol and with melarsen oxide, indicating that melarsoprol can be 
used for determination of arsenic sensitivity in vitro.  The isolates from the HAT patients 
were also sensitive to the trypanocides in current use (pentamidine and nifurtimox) and to DB 
75 the active principle in DB 289, a promising diamidine for oral treatment (Jannin & Cattand 
2004).  
 
These sensitivity tests were conducted on parasites that had been sub-passaged between four 
and seven times in rodents. It is an inherent problem with T. b. gambiense that drug 
sensitivities cannot be determined with trypanosomes isolated freshly from an infected 
patient, as these cells do not grow in vitro and have a very low virulence to rodents (Aerts et 
al. 1992;Dukes et al. 1989;Matovu et al. 2001a). Sub-passages in rodents are therefore 
inevitable; in this study we kept them at a minimum in order to preserve the nature of the 
isolates and prevent selection. 
 
Resistance to melarsoprol has been suggested to be due to reduced drug uptake. The P2 
nucleoside transporter mediates the uptake of melaminophenyl arsenicals (Carter & Fairlamb 
1993) and diamidines (Barrett et al. 1995;Carter et al. 1995). The transporter is encoded by 
the TbAT1 gene and recent studies indicated a possible link between particular TbAT1 alleles 
and occurrence of relapses (Maser et al. 1999;Matovu et al. 2001b). All the T. b. gambiense 
isolates analyzed here contained a full-size TbAT1 open reading frame. To date only in one 
isolate, T. b. gambiense K001 from Angola, has the TbAT1 gene been found deleted (Matovu 
et al. 2001b), indicating that deletion of TbAT1 may not occur frequently. The amplified 
genes lacked the ten mutations noted earlier in resistant isolates and were almost identical to 
the TbAT1 reference sequence from melarsoprol sensitive T. b. brucei. All sequences had one 
new coding mutation C1384T (resulting in P462S); a few sequences carried additional 
mutations (Table 2). All these mutations have not been reported before. Though their 
functional implications, if any, still need to be investigated, there is at present no evidence for 
TbAT1resistant-type alleles in the T. b. gambiense isolates characterized here. 
 
It is important to note that none of the eighteen patients had previously been treated with 
melarsoprol and hence there is no clinical evidence of resistance (melarsoprol stopped to be 
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used as the first-line drug in September 2001). Nevertheless the parasites were isolated from 
an area of very high rate of melarsoprol refractoriness (Moore & Richer 2001) and resistance 
to melarsoprol was shown to be stable even in the absence of drug pressure (Kaminsky et al. 
1989;Scott et al. 1996). 
 
In conclusion, all T. b. gambiense isolated from patients in south Sudan were sensitive to 
melarsoprol. At this point, we cannot formally exclude a bias against eventual melarsoprol-
resistant trypanosomes during isolation. Nevertheless, our results indicate that factors other 
than drug resistance may contribute to relapses from melarsoprol therapy. Recently isolated T. 
b. gambiense from Cote d`-Ivoire, Cameroon and DR Congo were also found to be sensitive 
to melarsoprol (R. Brun personal communication). Similarly in isolates from NW Uganda, 
there was little evidence of resistance in T. b. gambiense to melarsoprol (Matovu et al. 
2001a). These findings cast doubts on the current suggestion that melarsoprol resistant 
parasites are the cause of the high rate of treatment failures. Host factors and other parasite-
derived- factors, such as affinity of trypanosomes to extravascular sites that are less accessible 
to melarsoprol, also need to be investigated in order to explain the high melarsoprol relapse 
rates in certain sleeping sickness foci. A combination of factors may be responsible for the 
phenomena of melarsoprol treatment failures in T. b. gambiense patients (Brun et al. 2001). 
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 Melarsoprol Melarsen 
oxide 
Pentamidine Diminazene DB 75 Nifutimox 
STIB 930* 10.3 ± 6.7 6.5 ± 5.6 6.74 ± 1.6 8.98 ± 2.3 12.9 ± 0.8 1748 ±  189 
K03048 5.9 4.2 23.2 12.9 3.6 469.9 
K03043 2.1 3.3 8.3 5.6 9.4 1117.3 
K03030 4.7 2.3 11.7 4.7 4.4 1385.3 
K03028 5.7 2.4 6.1 2.1 13.3 2631.4 
K03042 3.8 2.5 6.3 16.1 18.4 417.7 
I04008 4.9 3.8 5.8 9.3 2.1 525.6 
K03051 3.9 4.0 17.0 8.8 13.9 341.1 
I04012 5.9 6.4 3.2 11.6 8.9 978.0 
I04019 8.5 2.7 14.3 10.1 17.8 1148.6 
I03030 2.5 1.3 7.4 7.1 13.5 396.8 
K03045 7.0 3.1 3.2 10.1 1.9 nd 
I03037 2.8 2.0 10.3 12.7 nd nd 
K03010 3.3 6.3 8.9 14.5 nd nd 
K03054 1.3 3.0 Nd 6.3 nd nd 
K03032 10.8 8.2 Nd 0.7 nd nd 
104021 8.8 7.3 Nd 1.9 nd nd 
Means 
for all 
isolates   
5 ±  1.47 3.9 ± 0.9 10.98 ±  0.9 8.68 ± 2.3 8.39 ± 0.9 928.4 ± 102 
 
 
Table 1: In vitro sensitivities of T. b. gambiense isolates from south Sudan. The 
results are from a hypoxanthine assay and are given as means of IC50  (nM) from four 
independent assays (mean  ± 2SD are shown for the reference strain and for the  
isolates combined ). *T. b. gambiense STIB 930 a melarsoprol sensitive isolate was 
used as the reference. 
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Isolate 
No. 
 Parasitaemia  No of animals that died 
during the experimental 
period (Days post infection)  
Days post 
infection  
4 8 12 15 19 26 33 40 47 52 60  
K03048 ++ ++ +++ +++ +++ +++ +++ ++ ++ n +++ 2 (23,35) 
K03043 ++ ++ ++ + + ++ n n n ++ N 1(28)  
K03042 ++ + n n n + ++ ++ n + ++ 0 
I04008 + + + + ++ ++ ++ n n + ++ 3(47,47, 47) 
K03051 +++ +++ +++ ++ +++       3 (4, 24, 24, 24) 
I03037 +++ ++ ++ ++ +++ +++ +++ ++ +++   4(34, 47, 49, 53) 
K03010 +++ ++ + ++ ++ n ++ ++ ++ +++ +++ 3(54, 55, 59) 
K03032 ++ + + ++ ++ + + + + ++ ++ 1(58) 
104021 + n + + ++ +++ +++ +++ +++ ++ +++ 0 
 
Table 2:  Infection pattern of nine human T. b. gambiense isolates in immunosuppressed 
and untreated Swiss White mice. Haematocrit centrifugation technique was used to 
estimate parasitaemia - graded as; n- negative, + (1-5), ++ (6-15) and +++ (more than 
15). All the trypanosome isolates had a pre-patent period of at most four days. 
Melarsoprol treated (2.5mg/ml for four consecutive days) mice were aparasitaemic 
from day 8 to the end of the experimental period and none died during the 60 day 
period (data not shown). 
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Position in 
gene 
 
76-78 83 1086 1168 1384 
 Isolate      
 TbATI s GTG A C A C 
 K03043 GTG A C A T** 
 K03030 GTG A C A T** 
 K03028 GTG A C A T** 
 I03037 GTG A C A T** 
 K03051 GTG A C A T** 
 I04008 GTG A C A T** 
 104022 GTG G** T*** A T** 
 K03045 GTG A C A T** 
 I04015 GTG A C A T** 
 I04015c GTG A T*** G*** T** 
 K03048 GTG A C A T** 
 K03048c ---* A C A T** 
 
 
Table 3: Comparison of the T. b. gambiense isolates amplified TbATI gene with TbATI 
sensitive
 (GenBank accession number AF152369) (Maser et al. 1999). A few mutations were 
noted; a coding mutation C1390T in all the isolates, another coding mutation (A83G) and a 
silent mutation (C1086T) in I04022. The cloned gene from 104015 and K03048 mutation at 
C1390T was also noted. Additional mutations were noted in cloned genes. The mutations 
resulted in *amino acid loss, **coding mutation, ***silent mutation. 
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CHAPTER 8: General Discussion 
 
This thesis was conducted under the auspices of the Eastern Africa Network for 
Trypanosomosis (EANETT). The network was founded in 1999 with a mission to improve 
control of animal and human African trypanosomosis in Eastern Africa. Member countries 
include Uganda, Kenya, Sudan, Tanzania, Malawi and Switzerland. Between the member 
institutions in these countries, the network aims at establishing collaboration in research, 
training and control of trypanosomosis, links for exchange of information and technologies. 
The study reported here is an example of the links developed by the network which enabled 
the work to be carried out in three of the member countries Sudan, Kenya and Switzerland. 
This thesis addresses one of the objectives of the network -to identify the reasons for 
melarsoprol treatment failures in T. b. gambiense sleeping sickness patients and thus enable 
the development of strategies for the treatment of refractory cases. In the EANETT member 
countries, high treatment failure rates have been reported in North West Uganda and southern 
Sudan. In Uganda, this  problem was being addressed by scientists in Livestock Research 
Institute (LIRI) (Matovu et al. 2001b;Matovu et al. 2001a) but no corresponding studies had 
been carried out in south Sudan. The current study focused on one of the areas in south Sudan, 
Ibba in Maridi county, where high treatment failure rates have also been reported. 
In the Maridi county, Médecins Sans Frontières France (MSF-F) runs a HAT control program 
that depends on case detection (passive and active surveillance) and treatment of the 
diagnosed patients at the Ibba MSF-F hospital. This was the only treatment centre for the 
second-stage disease serving both Maridi and Mundri counties. The high failures rates (20%) 
(Moore & Richer 2001) and high mortality after melarsoprol treatment led to poor recruitment 
of patients to this centre (MSF report, 2001). The efficacy of melarsoprol was questioned and 
it was replaced by eflornithine as the first-line drug for the second stage disease. However, 
this change was however done without determining the cause of the treatment failures but 
melarsoprol resistance has been suggested as a likely explanation. In line with current 
priorities (Brun et al. 2001;WHO 1998) our goal was to elucidate the role of drug resistant 
trypanosomes in the high rates of treatment failure. However, there were no recently isolated 
T. b. gambiense available and the first challenge was therefore to isolate parasites from the 
patients in this area. 
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Isolation of T. b. gambiense from HAT pateints 
 
Prior to the field studies, laboratory studies geared at improving the isolation protocols were 
carried out. We first had to determine the duration the liquid nitrogen in the tank and in the 
dry shippers would last. Scientific studies in areas experiencing conflict have several 
limitations and thus execution of even the best study protocols may not be successfully 
carried out on the ground.  This part of the study was done in collaboration with MSF-F. The 
organization has been working in the area since 1999. At the time of the study, MSF-F 
conducted HAT screening (passive and active) in the two Mundri and Maridi counties, and 
was running two treatment centres; first and second stage treatment centre at Kotobi in 
Mundri and at Ibba in Maridi County, respectively. As such the community had a lot of 
confidence in the organization. Some of the benefits of working under such an organization 
will be discussed briefly.  
 
a) Assurance of security  
The area has had civil war since 1952 and was under the control of the Sudan People 
Liberation Movement/Army (SPLM/A). In the market places and in other public places the 
ex-soldiers were never shy to show off their armory that ranged from modern guns, grenades 
to traditional machetes, bows and arrows. MSF-F remained in a state of general alert and 
maintained high security guidelines at all times. Bomb shelters and runaway bags were the 
first items visitors were introduced to. This was essential since attacks on MSF premises 
occasionally occurred and at such times all the foreign staff would be evacuated. Such 
interruption of the control activities led to the delay of the field studies for more than six 
months. 
 
b) Enormous resources are required for HAT investigation in the field 
 
Enormous resources (personnel and finances) are needed to undertake field work on HAT. 
The advantages of working within the established MSF-F program therefore cannot be 
underestimated. The longstanding civil war has led to destruction of the infrastructure and, 
worse, hindered the rebuilding. The only reliable mode of transportation within excursion into 
and out of the region was limited to air on the NGO’s cargo aircrafts. The area also 
experience heavy equatorial downpours and during such times, landing or take off on the 
earth airstrips are greatly a precarious affair. This becomes limiting since essential supplies 
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such as liquid nitrogen required for trypanosome storage were not available in south Sudan. 
Secondly there were no permanent roads and even on the best roads the maximum speed was 
only about 30 km/hour. Lack of public transport in the region meant that the MSF-F mobile 
team had i) to go into the villages to screen the communities, ii) transfer those diagnosed 
positive to the treatment centres iii) then transfer them back home after treatment. In 
summary, the field study had to coincide with the dry season, active screening surveys, flight 
in/out of Maridi and the area had to be relatively safe. 
 
Implication of main findings and suggestions for further research 
 
a) Cryopreservation and primary propagation of T. b. gambiense  
There are several possibilities to isolate bloodstream forms of T. b. gambiense from patients 
(Brun et al. 2001). However, cryopreservation of infected blood samples in liquid nitrogen 
and subsequent propagation in susceptible rodents has been suggested as the most promising 
approach and hence this method was used. Samples of blood from 50 HAT patients were 
cryopreserved in Triladyl®, stored in vapour nitrogen and airlifted to the Trypanosomiasis 
Research Centre (TRC) of KARI in Kenya. 
 
Successful isolation of trypanosomes depends on propagation of the stabilates in laboratory 
rodents. Previous studies have shown that propagation of T. b. gambiense is complicated by 
the low parasitaemia in patients and the limited susceptibility of common rodents (Aerts et al. 
1992;Matovu et al. 2001a). In this study the susceptibility was increased by using 
immunosuppressed Mastomys natalensis and Severe Combined Immunodeficient (SCID) 
mice for primary propagation. Eighteen T. b. gambiense cryosamples were, as a result, 
successfully propagated. These isolates are stored in two cryobanks at the TRC-KARI, 
Nairobi, and the Swiss Tropical Institute (STI), Basel. This is the first report of successful 
isolation of a large number of T. b. gambiense isolates from HAT patients. The isolates are an 
important resource especially for pre-clinical screening studies of up-coming trypanocidal 
compounds. 
 
Previous studies have reported low recovery rates or complete loss of T. b. gambiense 
populations following cryopreservation in medium containing 10% glycerol (Brun et al. 
2001;Matovu et al. 2001a). One main contribution of the present study is the improvement in 
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cryopreservation of T. b. gambiense (Chapter 3). The high recovery rate attained in this study 
may be attributed to the superior cryopreservation medium. Various teams have adopted the 
use of Triladyl cryomedium in T. b. gambiense isolation and higher isolation success has been 
achieved (Pyana et al. 2005). 
 
The SCID mice are highly susceptible to T. b. gambiense (Inoue et al. 1998) and in this study 
we found that the SCID mice are more susceptible than immunosuppressed M. natalensis. 
However, the SCID mice are expensive (40USD/mouse) and are not readily available in 
Africa. Secondly, because they are immunodeficient, they are prone to various infections and 
therefore require specific housing and maintenance conditions. As such they may not be the 
appropriate choice in some endemic countries in Africa. In such situations immunosuppressed 
M. natalensis may be used. 
 
In the present study, a colony of M. natalensis was established at KARI-TRC. The baseline 
biological reference values, reproductive performance as well as the optimum dosage regime 
of immunosuppression using cyclophosphamide, have also been established (Kagira et al. 
2005). Breeders from this colony may be used to initiate colonies in T. b. gambiense endemic 
countries. Indeed one of the EANETT objectives is to establish colonies in member countries 
including Sudan, Uganda and Tanzania as was agreed at the EANETT workshop on 
standardization in 2005. 
b) Propagation of T. b. gambiense in other species of mice 
 
Normal in-bred or out-bred laboratory mice are generally thought not to be susceptible to T. b. 
gambiense isolates. In this study, however, we found that immunosuppression of mice species 
with cyclophosphamide (300 mg/kg prior to infection and repeated once/week at 200 mg/kg) 
increases their susceptibility to T. b. gambiense.  Indeed, samples directly isolated from the 
patients were infective also for immunosuppressed Swiss White mice. In addition, at second 
passage, propagation of the isolates could be done in various species of mice but all species 
had to be immunosuppressed. Recently, it was described that Grammomys surdaster, which 
lives in mountains in Central Africa, is a good model for primary isolation of T. b. gambiense 
(Buscher et al. 2005). The G. surdaster are more nervous than laboratory rodents and 
experience is needed in handling them. The age appropriate for experimentation (15 weeks 
old) is also higher than that of laboratory mice (21 days).  
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This study recommends that primary propagation and the subsequent subpassage should be 
done in immunosuppressed M. natalensis or in SCID mice. Further subpassages can then be 
done in immunosuppressed laboratory mice (e.g. C57/bl or Balb/C). However, the choice 
should depend on what mice species is available and on the facilities in the specific 
laboratories. Available mice breeds should be screened after immunosuppression with 
cyclophosphamide at 300 mg/kg prior to infection and repeated once a week at 200 mg/kg. 
This propagation will allow the characterization of T. b. gambiense from various hot spots, 
hence enhancing the monitoring of drug resistant trypanosomes. 
c) Melarsoprol resistance in the T. b. gambiense isolates 
 
In the Ibba treatment centre, high treatment failure rates (Legros et al. 1999;Moore & Richer 
2001) and high mortality (MSF 2001) following melarsoprol treatment were considered 
serious. One of the major objectives of this PhD study was to determine whether the parasites-
T. b. gambiense are melarsoprol resistant. This was addressed in two ways; determining the 
sensitivity of parasites to the drug and characterizing the TbATI gene which is thought to be 
involved in drug resistance.  
i) Sensitivity tests 
At the time of parasite isolation, the treatment approach for the second stage disease had 
changed and eflornithine had replaced melarsoprol as the first-line drug. Currently, 
melarsoprol is only used in eflornithine relapse patients and therefore melarsprol relapse 
patients are few. Ideally, resistance studies should be carried out on parasites isolated from 
relapse patients. In view of the fact that resistance to melarsoprol is stable even in the absence 
of drug pressure (Kaminsky et al. 1989;Scott et al. 1996); it would be expected that the 
melarsoprol resistant populations would still be circulating among the patients. In this study, 
none of the eighteen patients from whom the T. b. gambiense were isolated had previously 
been treated with melarsoprol. 
There are various in vitro tests for determining the sensitivity of trypanosomes to trypanocides 
and to new compounds as reviewed by Kaminsky & Brun (1993). For sensitivity testing of 
field isolates the assay chosen should; i) not require pre-adapted trypanosomes ii) be able to 
distinguish between sensitive and resistant isolates iii) allow appropriate exposure of the 
parasites to the compound/trypanocidal drug . In this study we used the hypoxanthine 
incorporation assay since it meets these criterions (Brun et al. 1989;Brun & Kunz 1989;Brun 
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et al. 2001). Sensitivity tests indicated that the 18 T. b. gambiense isolates were sensitive to 
arsenicals (melarsoprol and Mel OX).  
 
These results are in agreement with previous studies. Recently isolated T. b. gambiense from 
Côte d’Ivoire, Cameroon and DRC were also found to be sensitive to melarsoprol (R. Brun 
personal communication). Similarly, earlier studies have not identified any difference in 
susceptibility between relapse and first treatment cases (Brun et al. 2001;Matovu et al. 
2001a). In addition, the isolates were sensitive to the trypanocides in current use 
(pentamidines and nifurtimox) as well as to DB 75, the active principle of DB 289, a 
promising drug for the 1st stage disease. 
 
The other contribution of the current study is on the use of melarsoprol for in vitro 
determination of arsenical sensitivity. The use of melarsoprol for in vitro determination of 
arsenical sensitivity has been questioned mainly because in plasma, melarsoprol is rapidly 
metabolized (96% within 1 hour) to form active metabolites including melarsen oxide. Mel 
OX is the active drug not melarsoprol (Keiser et al. 2000). Nevertheless most laboratories 
continue to use melarsoprol in tests since it is readily available as compared to Mel OX. This 
study has demonstrated that there is no difference in the IC50 values obtained with 
melarsoprol and with Mel OX, indicating that melarsoprol can be used for determination of 
arsenical sensitivity in vitro. 
 
ii) Nature of the TbATI gene in the isolates 
Melarsprol resistance has been induced in laboratory strains and was shown to be caused by 
loss of the P2 adenosine transporter that also mediates uptake of melarsoprol and diaminidines 
(Carter & Fairlamb 1993;Carter et al. 1995). The transporter is encoded by the TbAT1 gene 
(Maser et al. 1999;Matovu et al. 2003). The amplified TbATI gene of these Sudanese isolates 
were highly similar to that of the melarsoprol sensitive isolate (Maser et al. 1999). This 
further confirms the susceptibility test that the isolates are sensitive to melarsoprol. 
 
Recent studies indicate that TbATI may not be the only gene involved in melarsoprol 
resistance. Maser and Kaminsky (1998) identified the ABC transporters and over-expression 
of T. brucei MRPA has been shown to result in resistance to melarsoprol (Alibu et al. 2006). 
The gene is predicted to mediate efflux of melarsoprol. Since these isolates were sensitive to 
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melarsoprol it was not necessary to characterise expression of TbMRPA. In isolates showing 
melarsoprol resistance it would be important to determine its role. 
 
Markers for mapping melarsoprol resistance 
 
The question of the reliable marker for melarsoprol resistance is still unanswered. Recent 
studies indicate that TbATI and TbMRPA genes might be reliable genetic markers. However, 
the contribution of each of these genes in the field, in particular to melarsoprol treatment 
failures, is yet to be determined. Indeed, genetic markers for resistance provide a fast and easy 
assessment of the problem and it is not a wonder that most of the studies dealing with field 
isolates have focused on genetic markers of resistance. Recently, detection of arsenical drug 
resistance in T. brucei with a simple fluorescence test has been developed (Stewart et al. 
2005). These tests should be able to distinguish between melarsoprol resistant and sensitive 
phenotypes in the field. In addition, validation test should be carried out in various T. b. 
gambiense endemic areas.  
 
Before these tests are validated, the susceptibility tests should be viewed as the gold standard 
for determining melarsoprol resistance. The findings to date cast doubts on the suggestion that 
melarsoprol resistant parasites are the cause of the high rate of treatment failures reported. 
However, it is important to note that the number of isolates tested so far is still small and it is 
vital that isolation of T. b. gambiense from melarsoprol relapse patients continues. Under the 
EANETT the protocols for sensitivity testing were standardized at the 7th EANETT workshop 
and their use in various laboratories may provide results that are comparable (EANETT 
2005). 
 
Other possible causes of the melarsoprol treatment failure 
 
The current study did not identify the reason(s) for the high rates of treatment failure 
following melarsoprol treatment. As pointed out earlier by Brun et al. (2001), a combination 
of factors may be responsible for the phenomenon of melarsoprol treatment failure in HAT 
patients. Two factors, the parasite distribution in tissues and the melarsoprol dosage regime, 
are worthy further discussion. 
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a) Parasite distribution in tissues or organs 
The other parasite factor that may affect the efficacy of melarsoprol is the parasite distribution 
in the tissue or organs where the drug levels are sub-therapeutic. Such organs will serve as 
areas where the parasites proliferate irrespective of the drug levels in blood and may well 
serve as the sources of parasites for re-invasion after cessation of drug levels. In a recent study 
in mice, relapse populations did not show any difference in sensitivity to selected drugs. 
Unfortunately, investigations on the distribution of trypanosomes in these extra-vascular sites 
are not straight forward but there are indications that the spleen may be one site (Bernhard 
2006). Indeed T. b. gambiense is tissue invasive and the affinity of the parasite to extra-
vascular sites other than the CNS which are inaccessible to melarsoprol may be responsible 
for the relapses. Whether the different strains have varying affinities for the extravascular 
tissue is not clear and further studies are necessary. 
 
b) Melarsoprol dosage schedules, a possible cause of treatment failure  
 
Melarsoprol was introduced for treatment of HAT before its pharmacokinetic parameters were 
fully understood and therefore the recommended schedules were empirically developed. The 
recommended schedules depend on the region as shown in figure 1. 
 
Day of drug application 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 
Schedule used in Angola & Côte d’Ivoire 
M1 M2 M3 M3        M1 M2 M3 M3        M1 M2 M3 M3          
Schedule used in the Democratic Republic of Congo & Republic of Congo  
M3 M3 M3        M3 M3 M3        M3 M3 M3             
Schedule used in Equatorial Guinea, Central African Republic, Sudan & Uganda§ 
Mx Mx Mx       Mx Mx Mx       Mx Mx Mx               
 
M1=Melarsoprol 1.2 mg/kg bw; M2=Melarsoprol 2.4 mg/kg bw; M3=Melarsoprol 3.6 mg/kg bw (max. 5 ml) 
Mx=1 series of 1.8, 2.16, 2.52 mg/kg bw , 1 series of 2.52, 2.88, 3.25 mg/kg bw, 1 series of 3.6, 3.6, 3.6 mg/kg bw (max. 5 ml) 
 
Figure 1: The older melarsoprol dosage schedules for treatment of T. b. gambiense patients as 
recommended by the WHO (WHO, 1986). 
 
 
Further, differences in duration and mode of therapy have been observed depending on the 
country, local habits and the hospital involved. The different schedules would result in 
varying pharmacodynamics and therefore different responses in the patients. In fact, the high 
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frequency of relapses appears to be associated with the incremental dosage regimen of 
melarsoprol (Cross et al. 2006;Legros et al. 1999;Pepin & Mpia 2005;Schmid et al. 
2004b;Stanghellini & Josenando 2001). In the Ibba hospital the incremental dosage regime 
(regime c) was also used. Under this regime the first dosage (1.2 and 1.8mg/kg) is too low and 
hence the low total dosage may explain the relapse. Ideally the parasites should be exposed to 
trypanocidal levels during the three or four days of the series. However, when the first dosage 
is low, it means that the parasites are exposed to sub-therapeutic levels of melarsoprol and 
hence the series of dosage are in reality too short to eliminate all parasites.  
 
Current schedule of melarsoprol and the implication 
 
Various studies (Burri et al. 1993;Burri et al. 1994;Keiser et al. 2000) shed light on the 
pharmacokinetics of melarsoprol and enhanced the development of the 10 days treatment 
schedule. Trials of the schedule have been carried out in various endemic countries (Burri et 
al. 2000;Schmid et al. 2004a;Schmid et al. 2005b). This schedule was recommended in 2003 
by the International Scientific Council of Trypanosomiasis Research and Control (ISCTRC) 
as the schedule of choice in all T. b. gambiense endemic countries. In this new schedule the 
patient receives 2.16 mg/kg bwt for ten consecutive days, intravenously. 
 
This results in a sustained level of melarsoprol in the plasma, thus trypanosomes are exposed 
to a constant melarsoprol concentration for 10 days. Standardized treatment means that 
relapses will be more comparable. In addition, a shorter regime is less burdensome for the 
patient, families, and health workers and is more cost-effective (Schmid et al. 2005a). 
 
The recent findings (this PhD thesis and other studies) indicate that melarsoprol resitance 
might not be the cause of the high treatment failures reported. With this in mind and 
development of the new 10 treatment schedules, it would be reasonable to recommend 
melarsoprol use for the second stage disease. However, melarsoprol has another major 
limitation. It is highly toxic, with 5-10% of the treated patients developing acute 
encephalopathy and leading to fatality in approximately 50% of cases (WHO 1998). 
Concomitant infection with malaria is thought to increase the risk of encephalopathy (Pepin & 
Milord 1994). The other risk factors for encephalopathy include HIV (Blum et al. 2001), 
alcohol (Blum et al. 2001;Pepin & Milord 1994) and strenuous physical activity (Blum et al. 
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2001). Some of these risk factors cannot be entirely eliminated and thus high mortality will 
still limit the use of melarsoprol. 
Way forward for HAT chemotherapy 
 
a) Eflornithine  
Eflornithine is currently the drug of choice for the second stage disease in many treatment 
centres. Eflornithine treatment is associated with a low (2-3%) case-fatality (Milord et al. 
1992;Pepin et al. 2000) as compared to melarsoprol. Recently, the case-fatality rates and 
adverse effects of eflornithine (400 mg/kg per day for 14 days) and melarsoprol (2.2 mg/kg 
for 10 days) were compared in Kiri, Kajo-keji County. Eflornithine was shown to be safer 
than melarsoprol for the second stage disease. The case fatality rate is the lowest reported for 
second stage HAT. This safety has been confirmed in other treatment centres in Yei, Mundri 
and Maridi Counties (Chappuis et al. 2005). These findings further justify the preference of 
eflornithine over melarsoprol as the drug of choice for the treatment of the second stage 
disease of T. b. gambiense. 
 
Limitations of eflornithine in HAT treatment 
i) Intravenous eflornithine  
The major drawback of the intravenous eflornithine is related to its high cost of treatment and 
the inconveniences of administration, especially in understaffed rural hospitals of the endemic 
countries. About 56 i.v. infusions (100mg/kg every 6 hours for 14 days) are administered, the 
approximate cost of these infusion and hospitalisation is at least USD 270 (Van Nieuwenhove 
2000). This cost is still very high and the current challenge is oral administration of 
eflornithine (Na-Bangchang et al. 2004). 
 
ii) Immunodepression in the patients 
The other drawback of the current treatment regime is the use of eflornithine as 
monotheraphy. Eflornithine is trypanostatic, has a short half-life and thus has questionable 
efficacy in immunodepressed patients. Indeed, Milord et al. (1992) found that HAT patients 
co-infected with human immunodeficiency virus (HIV) responded poorly to eflornithine 
treatment. Earlier studies showed that HIV had no impact on epidemiology of HAT (Louis et 
al. 1991;Pepin et al. 1992b). Then, HIV was then relatively low in rural areas where HAT is 
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endemic. Today, the situation has changed and the prevalence of HIV is high even in rural 
areas and its role needs to be re-assessed.  
 
Apart from HIV, the effects of other concomitant infections that lead to immunodepression 
also need to be considered. For instance, a high occurrence of malaria in HAT patients has 
been reported (Schmid et al. 2004a;Wellde et al. 1989b;Wellde et al. 1989a). Individually, 
malaria and trypanosomiasis lead to parasite–induced immunodepression, and concerted 
immuno-depression from the two parasites may lead to an even more severe immuno-
depression in the host. 
 
Filariasis is another parasitic disease that is prevalent in central and western Africa and 
frequently reported in HAT patients (Enyaru et al., 2002). The strong Th1 known to occur in 
trypanosomosis infection is likely to counteract Th2 responses, which are necessary for 
immunity to helminths (Cox 2001;Dwinger et al. 1994). Thus it would be expected that in 
patients with multiple infection the immune system may not mount adequate response to all 
infections. It would be important for the treatment centres to also treat these other infections 
as this might improve the prognosis of the patients. 
 
It is imperative that the efficacy of eflornithine be protected by use in combination therapy 
rather than monotherapy (Moore 2005). One possible combination is eflornithine and 
melarsoprol. Experiments have shown synergism between eflornithine and melarsoprol 
(Jennings 1988b;Jennings 1988a;Jennings 1990). The few clinical studies carried out also 
indicate its effectiveness against melarsoprol resistant Gambian trypanosomosis (Mpia & 
Pepin 2002;Simarro & Asumu 1996).  
 
Alone and in combination with melarsoprol or eflornithine, nifurtimox has shown promise in 
the treatment of late stage of T. b. gambiense infections in melarsoprol refractory patients 
(Pepin et al. 1992a) Nifurtimox is being used for treatment of South American 
trypanosomosis (Chagas disease) but not registered for HAT. The ‘Drugs for Neglected 
Diseases initiative’ and WHO Special Programme on Research and Training in Tropical 
Diseases are currently assessing the utility and potential registration of nifurtimox for HAT. 
 
The recent five year donation of eflornithine, melarsoprol, nifurtimox, and pentamidine from 
Aventis to the WHO has made the drugs widely available for use. However, even though the 
General discussion 
__________________________________________________________________________ 
 112 
production of these drugs is temporarily assured, major efforts to improve the delivery of the 
drugs to the treatment centres are required. 
b) Prospects for development of new drugs for HAT 
 
The chemotherapy of HAT is greatly constrained by the limited number of drugs available. 
The situation is further complicated by the fact that in the last decades very few advances 
have been made. Sleeping sickness is transmitted mainly in rural Africa and thus has no 
profitable market that would encourage drug development (Nwaka & Ridley 2003).  
 
Drugs can be developed by random screening, using the knowledge from traditional medicine 
or rationally. There has been a lot of research on natural products/traditional medicines (Hoet 
et al. 2004;Freiburghaus et al. 1996a;Freiburghaus et al. 1996b;Freiburghaus et al. 
1997;Kubata et al. 2005) and the current challenge is to translate these insights into chemical 
insights that can form a basis for innovative drug discovery. Since 1999, the picture for drug 
development for neglected diseases has changed. Numerous partnerships between the public 
and private sectors have emerged to address this problem(Croft 2005). 
 
Remarkable advances have been achieved by an international consortium that is funded by the 
Bill and Melinda Gates Foundation. The consortium consists of various institutions including 
the STI, which is responsible for in vivo and in vitro evaluation of compounds. The 
consortium has identified a diamidine prodrug DB289 that is promising for oral treatment of 
early-stage disease (Jannin & Cattand 2004). The consortium continues the search for clinical 
candidates for the late stage disease. 
 
The other important initiative in trypanosomiasis is the ‘Drugs for Neglected Diseases 
Initiative’ (DNDi). It’s a global initiative to develop new affordable medicines for neglected 
diseases. The initiative catalyses and coordinates research, and manage drug development 
projects. It out sources most R&D activities - from discovery through predevelopment to 
development, including clinical trials - while maintaining leadership over the process (Pecoul 
2004).  
 
The current efforts in drug Research and Development may in the future provide new, 
effective, safe, and affordable drugs for the treatment of sleeping sickness. 
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APPENDIX 
STUDY OF REASONS FOR FAILURES AFTER MELARSOPROL TREATMENT IN 
SOUTH SUDAN 
 
 
 
 
Study undertaken by the Kenya Trypanosomiasis Research Institute, Kikuyu, and the Swiss 
Tropical Institute, Basel, Switzerland, in the framework of the Eastern Africa Network for 
Trypanosomosis (EANETT) 
 
Responsible for the study:   Prof. Reto Brun1 
Scientists carrying out the study:  Naomi Wangari Maina2 & Michael Oblere1 
1Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute 
(STI), P.O. Box, CH-4002 Basel, Switzerland. 
2Kenya Trypanosomiasis Research Institute (KETRI), P. O. Box 362, Kikuyu, Kenya 
 
 
 
Consent Form 
Section I – general information 
 
INFORMED CONSENT FOR: __________________________________________ 
 
What is your disease? 
You are suffering from sleeping sickness, a serious disease which untreated might progress 
and lead to death. 
 
What is the objective of the study? 
Sometimes treatment with melarsoprol is failing. It is not clear why this is happening. One 
possibility is that the parasites which cause disease are resistant to the drug. It is therefore of 
paramount importance to have parasite populations available for studies of resistance in the 
laboratory. 
 
What am I contributing to? 
Your participation may help to find the reasons for melarsoprol treatment failures. This will 
lead to better treatment strategies and help to cure more patients. 
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What should I do to participate in the study? 
In the course of your standard examination blood and cerebrospinal fluid have to be taken. 
Small amounts of your blood and spinal fluid will be frozen for subsequent studies. 
 
Can I refuse to participate in the research? 
Yes, you can refuse at any time to participate. If you refuse there will be no negative 
consequence. You receive treatment as appropriate. 
 
Will confidentiality be kept? 
Only the research team will have access to personal information. The samples will only be 
used for parasites only no further analysis on the samples will be done. Your anonymity and 
confidentiality will be safeguarded in any publication of the results of this research through 
use of pseudonyms. 
 
 
Section II – Signatures 
 
I agree to participate in the study to elucidate the reasons for failures after melarsoprol 
treatment, which involves collection of blood and cerebrospinal fluid. 
 
Name and signature of hospital staff who read and explained the above text: 
 
Name: ________________________              Signature: ____________________ 
 
 
Name and signature of participating patient or guardian: 
 
Name: ________________________         Thumb print/Signature: _____________________ 
 
Witness (hospital staff, only applicable if the subject and/or his guardian are illiterate): 
 
Name: _________________________         Thumb print/Signature: ____________________ 
 
Place and date:   ______________                   ___________________________ 
 
 
 
NB: The patients’ retained Section I of this consent form. Further information was also 
provided, the pictorial brochures on sleeping sickness was given to each patient to take 
home.  For the patients who gave consent, the questionnaire was filled out. Most of the 
patients/guardians could not read or write. As such the scientists assisted by an 
interpreter, usually a hospital assistant, asked the questions and filled the forms.  
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Questionnaire 
You have been purposively selected to participate in this study. In this part of the study, you 
will be asked a few questions and further information may be extracted from your hospital 
records. Please answer the questions to the best of your knowledge. Your participation may 
help to find the reasons for melarsoprol treatment failures. This will lead to better treatment 
strategies and help to cure more patients (Most of the patients/guardians could not read or 
write. As such the scientists assisted by an interpreter (hospital assistant) asked the questions 
and filled the forms) 
 (Fill in the information asked └─┴─┴─┴─┘, tick appropriate box   
Patient No. └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
Patient full name  └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
Date of admission └─┴─┘                  └─┴─┘             └─┴─┘ 
 ( d           m   m       y    y) Date of discharge └─┴─┘               └─┴─┘           └─┴─┘  ( d          m   m       y    y) 
Present residence    
 
                      
 County                 └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
  Payams             └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
   Bomas              └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
Probable place of 
infection          
  
                       
                          
 County                └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
 Payamas            └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
 Bomas              └─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
Age └─┴─┘ (Years) Sex          Male  (m)        Female   (f)  
Weight └─┴─┘ (kg) Height └─┴─┴─┘ (cm) 
How long ago were first signs observed   └─┴─┘ (Months)         └─┴─┘ (Years) 
Previous treatment for trypanosomiasis    yes    (y) no     (n) 
How many treatments have you had?           …………… 
 
Details of previous treatments for Trypanosomosis (if applicable) 
Treatment 
number 
Diagnosis 
Parasites in 
blood- (b 
CSF- (c 
 White cell 
counts in CSF 
Medication 
 Arsobal®   (a) 
Pentamidine   
(p) 
Nifurtimox  (n) 
DFMO (D) 
Not known   
(n) 
Where 
Private 
center  (p) 
Public 
center   (u) 
Was the treatment 
completed  
Yes   (y) 
No     (n) 
Do not know (d) 
How long 
ago 
1 month  
(m) 
6 months  
(s) 
1 year   (y) 
 2 years or 
more  (2y) 
Remarks  (if hospital 
record are available) 
1 
 
      
2 
 
      
NB : FOR MORE THAN THREE TREATMETENT ADDITONAL ROWS WOULD BE UDED. 
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PRESENT TREATMENT FOR TRYPANOSOMOSIS 
Name of 
responsible for 
treatment 
└─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
 
PRESENT TREATMENT: DAYS OF DRUG APPLICATION  
(Tick box  for each day when melarsoprol was applied, mark box with m for each day when Nifurtimox  
and  with D for each day  DFMO was applied) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
                         
If treatment deviates from normal schedule give justification in observations section (keywords only) 
 
LABORATORY EXAMINATIONS AT ADMISSION / DISCHARGE 
 
Before treatment After treatment 
Date of examination 
 
 
└─┴─┘└─┴─┘ └─┴─┘ └─┴─┘└─┴─┘ └─┴─┘ 
Consciousness 
 
 
Fully conscious  (p) 
Drowsy  (d) 
Comatose   (c) 
Fully conscious   (p) 
Drowsy   (d) 
Comatose    (c) 
Lymphadenopathy   
(Swollen neck lymph nodes) 
 
 
Absent  (a) 
Palpable  (p) 
 
(indicate only if > 1 cm) 
Serology 
     (If other than CATT used specify in field) CATT pos    (p) neg    (n) 
other    (o) 
n.d.   (b) 
 (If other test specify) 
└─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
Trypanosomes in lymph nodes 
 
 
Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy pos     (p) 
neg     (n) 
n.d.   (b) 
Trypanosomes in blood 
 
 
Microscopy 
(Blood smear) 
pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy 
(Blood smear) 
pos     (p) 
neg     (n) 
n.d.   (b) 
Trypanosomes in CSF 
 
 
Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy pos     (p) 
neg     (n) 
n.d.   (b) 
Double centrifugation of CSF used 
 
 yes    (y) 
no   (n) 
 yes     (y) 
no   (n) 
White blood cells in CSF (no / mm3) 
(Counting chamber) 
  
Microscopy 
└─┴─┴─┘ 
Microscopy 
└─┴─┴─┘ 
Malaria 
 
Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
 
Filariae (incl. Mansonella perstans) 
 
Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
(Specify species if possible) 
└─┴─┴─┴─┴─┴─┴─┴─┴─┘ 
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CLINICAL EXAMINATIONS AT ADMISSION / DISCHARGE  
 Before After   Before After 
 
Treatment 
  
Treatment 
Nutritional status 
(Circumference  
 of upper arm, cm) 
 
 
└─┴─.─┘ └─┴─.─┘ 
 Abnormal  
movements 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Fever (°C) 
 
 
 
└─┴─.─┘ └─┴─.─┘ 
 Walking disability yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Headache 
 
 
 
Yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 General motor 
weakness 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Pruritus 
 
 
 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 Unusual behavior yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Daytime sleep 
 
 
normal  (y) 
not  (n) 
normal  (y) 
not (n) 
 Inactivity yes   (y) 
no (n) 
yes   (y) 
no  n) 
Nighttime sleep 
 
 
normal  (y) 
not  (n) 
normal  (y) 
not  (n) 
 Aggressivity yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Tremor 
 
 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 Disturbed appetite 
(bulimia / anorexia) 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Speech impairment 
 
 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 
Check yes if any deviation from normal pattern are 
observed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
OTHER DRUGS USED 
(Indicate only drugs additional to regular treatment in this center) 
Additional drugs used yes   (y) no  (n) 
1. 
2.  
3.  
 
OBSERVATIONS AND OTHER DIAGNOSIS 
(For additional information and comments only; all entries must be written 
clearly readable) 
 
Date Remark Responsible for 
remark 
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Animal care and use 
All protocols involving laboratory animals were approved by the KETRI Institutional Animal Care 
and Use Committee (IACUC). 
 
 
 
 
Abbreviations 
 
 
BSF Bloodstream forms 
CAR Central Africa Republic 
CATT  Card agglutination Test for Trypanosomiasis 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DFMO    DL-a-difluoromethylornithine 
DMSO     Dimethylsulfoxide 
DNA        Deoxyribonucleic Acid 
DRC        Democratic Republic of Congo 
EANETT      Eastern Africa Network for Trypanosomosis 
HAT       Human African  Trypanosomosis 
HB      Haemoglobin 
HCT   Haematocrit centrifugation technique 
HIV     Human Immunodefiency Virus 
IC50             Drug concentration inhibiting parasite growth by 50% 
IMC      International Medical Corps 
ISTRC  International Scientific Council of Trypanosomiasis Research and Control 
KARI      Kenya Agricultural Research Institute 
Mel B       Melarsoprol 
Mel OX         Melarsen oxide 
MEM       Minimum essential medium 
MIC Minimum inhibitory concentration 
MSF        Médecines Sans Frontièrs 
NGO               Non-Governmental Organizations 
PCV                Packed cell volume 
SPLM/A      Sudan’s People Liberation Movement/Army 
SRA           Serum Resistance Associated gene  
SS Sleeping Sickness 
STI Swiss Tropical Institute 
TgsGP        T. b. gambiense specific  glycoprotein   
TRC                Trypanosomiasis Research Centre 
WBC         Total white cell 
WCC             White cell count 
WHO             World Health Organization 
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